This may include, but is not limite d to, redaction of the following: 
ï‚·Named persons or organizations associated with the study.ï‚·
â€¢Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.Title: An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects with Moderately to
Severely Active Crohnâ€™s Disease Treated With Vedolizumab IV
Effect of Vedolizumab IV on Mucosal Healing in Crohnâ€™s Disease
Study ID: [REMOVED]
SAP Approve Date: 21 March 2018
Certain information  within this Statistical Analysis Plan has been redacted (ie, specific content 
is masked irreversibly from
 view with a black bar) to protect either personally identifiable 
information or company confidential information. 
Proprietary information, such as scales or coding systems, which are considered confidential
information under prior agreements with license holder.
3DJHRI
3ULQWHGRUGRZQORDGHGGRFXPHQWVPXVWEHYHULILHGDJDLQVWWKHHI IHFWLYHYHUVLRQ
&21),'(17,$/,1)250$7,21
'RQRWGLVWULEXWHRXWVLGHRI 7DNHGDZLWKRXWDFRQILGHQWLDOLW\D JUHHPHQW7$.('$'(9(/230(17&(17(5
67$7,67,&$/$1$/<6,63/$1
678'<180%(50/1
$Q2SHQ/DEHO3KDVHE6WXG \WR$VVHVV0XFRVDO+HDOLQJLQ6XEMH FWVZLWK0RGHUDWHO\WR
6HYHUHO\$FWLYH&URKQÂ¶V'LVH DVH7UHDWHG:LW K9HGROL]XPDE,9
(IIHFWRI9HGROL]XPDE,9RQ0XF RVDO+HDOLQJLQ&URKQÂ¶V'LVHDVH 
3+$6(%
9HUVLRQ)LQDO
'DWH0DUFK
3UHSDUHGE\ 
&21),'(17,$/3523(57<2)7$.('$ 
7KLVGRFXPHQWLVDFRQILGHQWLDOFRPPXQL FDWLRQRI7DNHGD$FFHSW DQFHRIWKLVGRFXPHQW
FRQVWLWXWHVWKHDJUHHPHQWE\ WKHUHFLSLHQWWKDWQRLQIRUPDWLRQ FRQWDLQHGKHUHLQZLOOEHSXEOLVKHG
RUGLVFORVHGZLWKRXWZULWWHQDXWKRUL] DWLRQIURP7DNHGDPPD
3DJHRI
3ULQWHGRUGRZQORDGHGGRFXPHQWVPXVWEHYHULILHGDJDLQVWWKHHI IHFWLYHYHUVLRQ
&21),'(17,$/,1)250$7,21
'RQRWGLVWULEXWHRXWVLGHRI 7DNHGDZLWKRXWDFRQILGHQWLDOLW\D JUHHPHQW $33529$/ 6,*1$785(6
6WXG\7LWOH $Q2SHQ/DEHO3KDVHE6WXG \WR$VVHVV0XFRVDO+HDOLQJLQ6XEMH FWV
:LWK0RGHUDWHO\WR6HYHUHO\$FWLYH&URKQÂ¶V'LVHDVH7UHDWHG:LWK 
9HGROL]XPDE,9 
7'&$SSURYDOV
'DWH
'DWH
'DWH
'DWHPPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
 
Page 3 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 2.0 TABLE OF CONTENTS 
1.0 TITLE PAGE 1 
1.1 APPROVAL  SIGNATURES ..........................................................................................  2 
2.0 TABLE OF CONTENTS ..................................................................................................................  3 
3.0 LIST OF ABBREVIATIONS ............................................................................................................ 5  
4.0 OBJECTIVES .................................................................................................................................. 7  
4.1 PRIMARY OBJECTIVE  ....................................................................................................... 7  
4.2 SECONDARY OBJECTIVES  ................................................................................................  7 
4.3 ADDITIONAL OBJECTIVES ................................................................................................ . 7 
4.4 STUDY DESIGN  ...............................................................................................................  8 
5.0 ANALYSIS ENDPOINTS ...............................................................................................................  10 
5.1 PRIMARY ENDPOINT  ...................................................................................................... 10 
5.2 SEC
ONDARY ENDPOINTS  ...............................................................................................  10 
5.3 ADDITIONAL ENDPOINTS  ...............................................................................................  10 
6.0 DETERMINATION OF SAMPLE SIZE ..........................................................................................  13 
7.0 METHODS OF ANALYSIS AND PRESENTATION ...................................................................... 14 
7.1 GENERAL PRINCIPLES  ................................................................................................... 14  
7.1.3  Definition of Baseline Values ......................................................................................  14 
7.1.4  Definition of Screen Failure ........................................................................................  15 
7.1.5  Definitions of Study Visit Windows .............................................................................  15 
7.1.6  Convention for Calculation of SES-CD Scores ..........................................................  18 
7.1.7  Convention for Calculation of CDAI Scores ...............................................................  18 
7.1.8  Conventions for Missing Adverse Events Dates ........................................................  20 
7.1.9  Conventions for Missing Concomitant Medications Dates ......................................... 21 
7.1.10  Conventions for Missing Previous Medications Dates ...............................................  21 
7.1.11  Conventions for Calculation of Duration of CD ...........................................................  22 
7.2 ANALYSIS SETS ............................................................................................................  22 
7.3 DISPOSITION OF SUBJECTS  ...........................................................................................  23 
7.4 MAJOR PROTOCOL VIOLATIONS  .....................................................................................  24 
7.5 SIGNIFICANT PROTOCOL DEVIATIONS  .............................................................................  25 
7.6 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  ..........................................................  25 
7.7 MEDICAL HISTORY AND CONCURRENT MEDICAL CONDITIONS  ......................................... 26 
7.8 MEDICATION HISTORY AND CONCOMITANT MEDICATIONS  ...............................................  27 
7.9 STUDY DRUG EXPOSURE AND COMPLIANCE  ................................................................... 28 
7.10  EFFICACY ANALYSIS ...................................................................................................... 28 
7.10.
1 Primary Efficacy Endpoint ..........................................................................................  29 
7.10.2  Secondary Efficacy Endpoints ....................................................................................  29 
 
Page 4 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.10.3  Additional Efficacy Endpoints .....................................................................................  31 
7.11  PHARMACOKINETIC/P HARMACODYNAMIC ANALYSIS  ........................................................  36 
7.12  OTHER OUTCOMES  ....................................................................................................... 36 
7.12.1  IBDQ ...........................................................................................................................  36 
7.12.2  EQ-5D Questionnaire ................................................................................................ . 37 
7.12.3  WPAI- CD ....................................................................................................................  37 
7.13  SAFETY ANALYSIS  ......................................................................................................... 37 
7.13.
1 Adverse Events .......................................................................................................... 37 
7.13.2  Clinical Laboratory Evaluations ..................................................................................  41 
7.13.3  Vital Signs ...................................................................................................................  43 
7.13.4  12-Lead ECGs ............................................................................................................  44 
7.13.5  Other Observations Related to Safety ........................................................................ 44 
7.14  INTERIM ANALYSIS  ........................................................................................................ 44 
7.15  CHA
NGES IN THE STATISTICAL ANALYSIS PLAN ...............................................................  46 
8.0 REFERENCES ...............................................................................................................................  47 
9.0 APPENDICES ................................................................................................................................  48 
 
 
 
Page 5 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 3.0 LIST OF ABBREVIATIONS 
AE adverse event  
AESI adverse event of special interest  
ALT alanine transaminase  
AST aspartate transaminase  
AVA anti-vedolizumab antibody; also called HAHA  
BMI body mass index  
CD Crohnâ€™s disease  
CDAI Crohnâ€™s Disease Activity Index  
CI confidence interval  
CRP C-reactive protein  
DBP diastolic blood pressure  
ECG electrocardiogram  
eCRF electronic case report form  
eGFR estimated glomerular filtration rate  
EQ-5D Euro Quality of Life -5D 
ET early termination  
FAS full analysis set  
FSH follicle-stimulating hormone  
GGT Î³-glutamyl transferase  
GHAS Global Histological Disease Activity Score  
GI gastrointestinal  
HAHA human antihuman antibody  
HBsAg hepatitis B  surface antigen  
hCG human chorionic gonadotropin  
HCV hepatitis C virus  
HIV human immunodeficiency virus  
HLT high level term  
HRQOL health-related quality of life  
IBDQ inflammatory bowel disease questionnaire  
INR international normalized ratio  
IRR infusion-related reactions  
IV intravenous  
LOCF Last available post -baseline Observation Carried Forward 
MaRIA Magnetic Resonance Index of Activity  
MAV markedly abnormal value  
MedDRA  Medical Dictionary for Regulatory Activities  
MR magnetic resonance  
MREn magnetic resonance enterography  
PML progressive multifocal leukoencephalopathy  
PPS per protocol set  
PRO patient reported outcome  
PT preferred term  
PT prothrombin time  
PTE pretreatment event  
QOL quality of life  
RAMP Risk Assessment and Minimization for PML  
RBC red blood cell  
SAE serious adverse event  
SBP systolic blood pressure  
SD standard deviation  
SES-CD simple endoscopic score for Crohnâ€™s Disease  
SI International System of Units  
SMQ standard MedDRA query  
 
Page 6 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 SOC system organ class  
TEAE treatment emergent adverse event  
TNF-Î± tumor necrosis factor -alpha 
URTI upper respiratory tract infection  
VAS visual analog scale  
WBC white blood cell  
WHODrug  World Health Organization Drug Dictionary  
WPAI Work Productivity and Activity Impairment  
WPAI-CD Work Productivity and Activity Impairment for Crohnâ€™s Disease  
 
 
Page 7 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 4.0 OBJECTIVES 
4.1 P RIMARY OBJECTIVE  
The primary objective of this study is to evaluate endoscopic remission of Crohn's Disease (CD) 
at Week 26 as assessed by ileocolonoscopy. 
4.2 S ECONDARY OBJECTIVES  
The secondary objectives for Study Part A are: 
ï‚· To examine the relationship among endoscopic, imaging, histological, and clinical 
assessments of CD . 
ï‚· To evaluate endoscopic remission at Week 14. 
ï‚· To evaluate endoscopic response at Weeks 14 and 26. 
ï‚· To evaluate clinical response assessed by Crohnâ€™s Disease Activity Index (CDAI) at 
Weeks 10 and 26. 
ï‚· To evaluate clinical remission assessed by CDAI at Weeks 10 and 26.  
The secondary objectives for Study Part B are: 
ï‚· To examine the relationship among endoscopic, imaging, histological, and clinical 
assessments of CD. 
ï‚· To evaluate endoscopic remission at Week 52. 
ï‚· To evaluate endoscopic response at Week 52. 
ï‚· To evaluate clinical response assessed by CDAI at Week 52. 
ï‚· To evaluate clinical remission assessed by CDAI at Week 52. 
ï‚· To evaluate durable endoscopic remission at Week 52 in patients with endoscopic 
remission at Week 26.  
4.3 A DDITIONAL OBJECTIVES  
The additional objectives for Study Part A are: 
ï‚· To evaluate changes in transmural bowel wall activity and other measures of bowel wall 
inflammation using magnetic resonance enterography (MREn) at Week 26.  
ï‚· To assess histological response at Week 26. 
ï‚· To evaluate C-reactive protein (CRP) at Weeks 10 and 26. 
ï‚· To evaluate fecal calprotectin at Weeks 14 and 26. 
ï‚· To evaluate immunogenicity of vedolizumab. 
ï‚· To evaluate health-related quality of life (as assessed by inflammatory bowel disease 
questionnaire [IBDQ] and Euro Quality of Life-5D [ EQ-5D]) at Weeks 14 and 26. 
 
Page 8 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· To explore the relationship between endoscopic remission and health-related quality of 
life (QOL). 
ï‚· To evaluate impact on loss of work productivity and activity impairment assessed by 
Work Productivity and Activity Impairment (WPAI):CD at Weeks 14 and 26. 
The additional objectives for Study Part B are: 
ï‚· To evaluate changes in transmural bowel wall activity and other measures of bowel 
wall inflammation using MREn at Week 52. 
ï‚· To assess histological response at Week 52 . 
ï‚· To evaluate CRP at Weeks 38  and 52. 
ï‚· To evaluate fecal calprotectin at Weeks 38 and 52. 
ï‚· To evaluate immunogenicity of vedolizumab. 
ï‚· To evaluate clinical response assessed by CDAI at Weeks 38 and 46. 
ï‚· To evaluate clinical remission assessed by CDAI at Weeks 38 and 46. 
ï‚· To evaluate health-related quality of life (IBDQ and EQ-5D) at Weeks 38  and 52. 
ï‚· To explore the relationship between endoscopic remission and health-related QOL. 
ï‚· To evaluate impact on loss of work productivity and activity impairment assessed by 
WPAI:CD at Week 52.  
4.4 S TUDY DESIGN 
This is a phase 3b single-arm, open -label multicenter study to evaluate the efficacy and safety of 
vedolizumab 300 mg intravenous ( IV) infusion over a 26-week treatment period using 
ileocolonoscopy for the assessment in subjects with moderately to severely active CD (Study 
Part A) followed by a 26-week treatment extension period (Part B). Biopsies will be collected for 
histological assessments per the schedule of events for all subjects. The study will be conducted 
at sites in North America and Europe. The 26-week treatment extension (Study Part B) is 
included as part of Protocol Amendment No. 04 (dated 27 April 2016), ongoing subjects at the 
time of the amendment will have the option to either stop treatment at Week 26 (Study Part A) or 
continue treatment into Part B. Subjects who enroll into the study after Protocol Amendment No. 
04 will be treated directly for 52 weeks (Study Parts A and B). 
Approximately 100 subjects with moderately to severely active CD who have failed treatment 
with corticosteroids, immunosuppressants, and/or biologics will be enrolled. Subjects who are 
tumor necrosis factor-alpha (TNF-Î±) antagonist naÃ¯ve as well as those who are TNF-Î± antagonist 
failures will be included, such that approximately 50% of enrolled subjects are TNF-Î± antagonist 
naÃ¯ve.  
The study consists of a 4-week screening period, a 26-week treatment period (Study Part A),  
followed by a 26-week extension treatment period (Part B from 7 days after Week 26 to 52 with 
last dose at Week 46), and an 18-week follow-up period following the last dose. The duration of 
the study will be approximately 44 weeks for subjects completing Study Part A and 70 weeks for 
subjects completing Study Part B. All subjects included in the study will also have a 6 month 
 
Page 9 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 safety follow-up telephone call following last dose. End of trial will be the date of the last visit of 
the last subject at the Postdose 18 Week Safety Follow-up visit. 
Subjects that meet all the inclusion criteria and none of the exclusion criteria will be dosed on 
site with vedolizumab 300 mg IV. Subjects will visit the site for dosing at Day 1, Weeks 2, 6, 14, 
and 22 for Study Part A and at Weeks 30, 38, and 46 for Study Part B. Ileocolonoscopy will be 
pe
rformed at the Screening, Week 14, Week 26 (Study Part A), and Week 52 (Study Part B) or 
early termination (ET) visits. Biopsies will be taken during the Screening, Week 26 (Study Part 
A), and Week 52 (Study Part B) or ET visit. All ileocolonoscopies will be evaluated by a blinded 
central reader.  
An MREn substudy will be conducted at selected qualified centers using a standardized magnetic 
resonance ( MR) acquisition and procedure to assess bowel wall activity. Only subjects from the 
pre-selected sites will be included in this study; these subjects will undergo an MREn assessment 
at the Screening, Week 26 (Study Part A), and Week 52 (Study Part B) or ET visit, unless they 
have contraindications to the procedure. All MREn results will be evaluated by a blinded 
independent central reader. 
Additional procedures will be performed according to the Schedule of Study Procedures 
(Appendix A ). 
Figure 4.a Schematic of Study Design - For Subjects on 26 Weeks of Treatment 
 
Figure 4.b Schematic of Study Design - For Subjects on 52 Weeks of Treatment 
 

 
Page 10  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 5.0 ANALYSIS ENDPOINTS 
5.1 P RIMARY ENDPOINT 
The primary endpoint is the proportion of subjects achieving endoscopic remission at Week 26. 
Endoscopic Remission is assessed by ileocolonoscopy and defined as simple endoscopic score 
for Crohnâ€™s Disease (SES-CD) score of â‰¤ 4. 
5.2 S ECONDARY ENDPOINTS  
The secondary endpoints for Study Part A are: 
ï‚· Proportion of subjects achieving complete mucosal healing at Week 26. Complete 
mucosal healing is defined as absence of ulceration. 
ï‚· Proportion of subjects achieving endoscopic remission at Week 14.  
ï‚· Proportion of subjects with endoscopic response at Week 14. Endoscopic response is 
defined as SES-CD reduction by â‰¥ 50%.  
ï‚· Proportion of subjects with endoscopic response at Week 26.  
ï‚· Proportion of subjects achieving clinical response at Week 10. Clinical response is 
defined as CDAI decrease from Baseline of â‰¥ 100 points.  
ï‚· Proportion of subjects achieving clinical response at Week 26. 
ï‚· Proportion of subjects achieving clinical remission at Week 10. Clinical remission is 
defined as CDAI â‰¤ 150.  
ï‚· Proportion of subjects achieving clinical remission at Week 26. 
The secondary endpoints for Study Part B are: 
ï‚· Proportion of subjects achieving complete mucosal healing at Week 52. Complete 
mucosal healing is defined as absence of ulceration. 
ï‚· Proportion of subjects achieving endoscopic remission at Week 52. 
ï‚· Proportion of subjects with endoscopic response at Week 52. Endoscopic response is 
defined as SES-CD reduction by â‰¥ 50%.  
ï‚· Proportion of subjects achieving clinical response at Week 52. Clinical response is 
defined as CDAI decrease from Baseline of â‰¥ 100 points.  
ï‚· Proportion of subjects achieving clinical remission at Week 52. Clinical remission is 
defined as CDAI â‰¤ 150.  
ï‚· Proportion of subjects with durable clinical remission.  Durable clinical remission is 
defined as clinical remission at Week 26 and Week 52. 
5.3 A DDITIONAL ENDPOINTS  
The additional endpoints for Study Part A are: 
 
Page 11  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Change from Baseline to Week 26 in individual MREn parameters (including wall 
thickening, relative contrast enhancement, presence of ulcerations, presence of 
edema) for each ileocolonic segment and for more proximal bowel segments, if 
evaluable.  
ï‚· Proportion of subjects achieving Magnetic Resonance Index of Activity (MaRIA) 
score <7 at Week 26 globally and on a per segment basis.  
ï‚· Proportion of subjects with 25% and 75% reduction of SES-CD at Weeks 14 and 26.  
ï‚· Proportion of subjects with no granulocytes present in bowel biopsy at Week 26. 
ï‚· Proportion of subjects with a change in histology at Week 26.  
ï‚· Proportion of subjects with elevated CRP at Baseline who achieve normalization of 
CRP at Weeks 10 and 26.  
ï‚· Change from Baseline to Weeks 14 and 26 in fecal calprotectin. 
ï‚· Proportion of subjects positive for anti-vedolizumab antibody (AVA; also called 
human antihuman antibody [HAHA]) at Baseline, Week 26,  and at the Postdose 18 
Week Safety Follow-up Visit.  
ï‚· Proportion of subjects with positive neutralizing AVA at Baseline, Week 26, and at 
the Postdose 18 Week Safety Follow-up Visit.  
ï‚· Change from Baseline to Weeks 14 and 26 in the IBDQ total and subscale scores.  
ï‚· Change from Baseline to Weeks 14 and 26 in the EQ-5D utility score and visual 
analog scale (VAS) score.  
ï‚· Change from Baseline to Weeks 14 and 26 in percent work time missed due to CD.  
ï‚· Change from Baseline to Weeks 14 and 26 in percent impairment while working due 
to CD.  
ï‚· Change from Baseline to Weeks 14 and 26 in percent overall work impairment due to 
CD.  
ï‚· Change from Baseline to Weeks 14 and 26 in percent activity impairment due to CD.  
ï‚· Adverse events (AEs), serious AEs (SAEs), vital signs, and laboratory tests. 
The additional endpoints for Study Part B are: 
ï‚· Change from Baseline to Week 52 in individual MREn parameters (including wall 
thickening, relative contrast enhancement, presence of ulcerations, presence of 
edema) for each ileocolonic segment and for more proximal bowel segments, if 
evaluable. 
ï‚· Proportion of subjects achieving MaRIA score < 7 at Week 52 globally and on a per 
segment basis.  
ï‚· Proportion of subjects with 25% and 75% reduction of SES-CD at Week 52. 
ï‚· Proportion of subjects with no granulocytes present in bowel biopsy at Week 52. 
 
Page 12  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Proportion of subjects with a change in histology at Week 52.  
ï‚· Proportion of subjects with elevated CRP at Baseline who achieve normalization of 
CRP at Weeks 38 and 52. 
ï‚· Change from Baseline to Weeks 38 and 52 in fecal calprotectin. 
ï‚· Proportion of subjects positive for AVA at Week 52 and at the Postdose 18 Week 
Safety Follow-up Visit.  
ï‚· Proportion of subjects with positive neutralizing AVA at Week 52 and at the Postdose 
18 Week Safety Follow-up Visit.  
ï‚· Proportion of subjects achieving clinical response at Weeks 38 and 46.  Clinical 
response is defined as CDAI decrease from Baseline of â‰¥ 100 points. 
ï‚· Proportion of subjects achieving clinical remission at Weeks 38 and 46. Clinical 
remission is defined as CDAI â‰¤ 150. 
ï‚· Change from Baseline to Weeks 38 and 52 in the IBDQ total and subscale scores.  
ï‚· Change from Baseline to Weeks 38 and 52 in the EQ-5D utility score and VAS score. 
ï‚· Change from Baseline to Week 52 in percent work time missed due to CD.  
ï‚· Change from Baseline to Week 52 in percent impairment while working due to CD.  
ï‚· Change from Baseline to Week 52 in percent overall work impairment due to CD.  
ï‚· Change from Baseline to Week 52 in percent activity impairment due to CD.  
ï‚· AEs, SAEs, vital signs, and laboratory tests. 
 
Page 13  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 6.0 DETERMINATION OF SAMPLE SIZE 
A sample size of 100 subjects will be sufficient to provide a 95% confidence interval based on 
normal approximation for the primary endpoint (endoscopic remission rate at Week 26) that 
extends no more than 10% in each direction from the estimated rate. 
 
Page 14  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.0 MET HODS OF ANALYSIS AND PRESENTATION 
7.1 G ENERAL PRINCIPLES  
Where appropriate, variables will be summarized descriptively by study visit and subgroups. For 
categorical variables, counts and proportions will be tabulated. Percentages will be calculated out 
of the total number of patients in the analysis set and by subgroups, when applicable. 
Percentages will be presented to 1 decimal place. Every effort will be made to limit the amount 
of missing data; however, if any missing data is present in the clinical database, a Missing 
category will be added in the tabulation, unless otherwise stated. 
For continuous variables, the number of subjects with non-missing values, mean, median, 
standard deviation ( SD), minimum, and maximum values will be tabulated. Means and medians 
will be presented to 1 more decimal place than the recorded data. The SDs will be presented to 2 
more decimal places than the recorded data. Confidence intervals about a parameter estimate will 
be presented using the same number of decimal places as the parameter estimate. 
All confidence intervals will be reported as 2-sided and will be assessed at the Î±=0.05 
significance level. No inferential statistics are planned for this study. 
The data summaries will be accompanied by individual subject data listings. 
A windowing convention will be used to determine the analysis value for a given study visit for 
observed data analyses. Details are provided in section  7.1.5. 
All statistical analyses will be conducted using SAS SystemÂ® Version 9.2, or higher. 
7.1.1 Study Terms and Definitions 
Study terms and definitions are provided below. 
Term  Definition  
Endoscopic Remission  SES-CD score â‰¤ 4  
Complete Mucosal Healing  Absence of ulcerations  
Endoscopic Response  SES-CD reduction by â‰¥ 50%  
Clinical Response  CDAI decrease from baseline of â‰¥ 100 points  
Clinical Remission  CDAI â‰¤ 150 points  
7.1.2 Definition of Study Days 
Study Day 1 is defined as the date on which a subject is administered their first dose of the 
medication, as recorded on the electronic case report form (eCRF) dosing page. Other study days 
are defined relative to the Study Day 1 with Day 1 being Study Day 1 and Day -1 being the day 
prior to Study Day 1. 
All protocol-specified study visit dates are defined relative to Study Day 1 (for example, the date 
for the scheduled Week 2 Visit should be Study Day 15). 
7.1.3 Definition of Baseline Values 
Unless otherwise specified, baseline values are defined as the last observed value before the first 
dose of study medication. Values measured on Day 1 must be prior to administration of study 
medication to be classified as Baseline. 
 
Page 15  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.1.4 Definition of Screen Failure 
Screen failure subjects are subjects who signed the informed consent and were not enrolled in the 
study. The primary reason for screen failure is collected in the eCRF using the following 
categories: 
ï‚· Pretreatment Event (PTE)/AE 
ï‚· Did Not Meet Entrance Criteria 
ï‚· Significant Protocol Deviation 
ï‚· Lost to Follow-Up 
ï‚· Voluntary Withdrawal 
ï‚· Study Termination 
ï‚· Other 
7.1.5 Definitions of Study Visit Windows 
Day 1 will be analyzed as Day 1, provided that the date of the assessment matches the date of the 
first dose of study drug. Assessments recorded as Day 1 on the eCRF but occurring prior to the 
date of first dose will be windowed to Baseline. 
Unless otherwise specified the rules provided below in Table 7.a, Table 7.b , Table 7.c, and Table 
7.d will be used for all variables. The lower and upper bounds of each window are the 
approximate midpoints between the scheduled days for the current visit and its adjacent 
scheduled visits. The value used in analysis for by-visit summaries is the value within the 
specified window. If a patient has more than one measurement within an analysis window, the 
assessment closest to the target day will be used. In case of ties between observations located on 
different sides of the target day, the later assessment will be used in analyses. In case of ties 
located on the same side of the target day (i.e., more than one value for the same day), the mean 
of the values will be used for continuous parameters and the worst result will be chosen over a 
more positive one for categorical parameters (i.e., an abnormal electrocardiogram [ECG] value 
will be chosen over a normal ECG value).  
For safety measurements (laboratory tests and vital signs), descriptive statistics are presented for 
each scheduled visit including the Final Visit. Final Visit during the Treatment Period will be 
defined as the last visit (inclusive of both scheduled and unscheduled) which falls between 
Baseline and Week 26 or date of early termination, whichever comes first, using the visit 
analysis windows defined above. Final Visit during the Treatment Extension Period will be 
defined as the last visit (inclusive of both scheduled and unscheduled) which falls just after 
Week 26 and up to Week 52 or date of early termination, whichever comes first, using the visit 
analysis windows defined above. 
Data identified on the eCRF as coming from an â€œunscheduledâ€ visit will be eligible for 
windowing and Final Visit summaries. There will not be a separate â€œunscheduledâ€ categorization 
for the reporting of these observations. 
The visit windows and applicable study day ranges are presented below for study.  
 
Page 16 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Table 7.a Visit Analysis Windows for Efficacy Variables Evaluated by Visit (Subjects on 26 Weeks of Treatment) 
Visit  Target Day  CDAI Scheduled at 
Baseline and Weeks 6, 10, 
14,  and 26  AVA, Biopsies, and MREn 
Scheduled at Baseline and 
Week 26  C-reactive protein 
Scheduled at Baseline and 
Weeks 10 and 26  Ileocolonoscopy Scheduled 
at Baseline and Weeks 14 
and 26 Fecal calprotectin and 
PRO related QOLs 
Scheduled at Baseline and 
Weeks 14 and 26  
Baseline 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 
Week 2 15      
Week 6 43 2 â€“ 56     
Week 10 71 57 â€“ 84  2 â€’ 126   
Week 14 99 85 â€“ 140   2 â€“ 140 2 â€“ 140 
Week 22 155      
Final / Week 26  183 141 â€“ 224 2 â€“ 232 127 â€’ 224 141 â€“ 232 141 â€“ 224 
 
Table 7.b  Visit Analysis Windows for Safety Variables Evaluated by Visit (Subjects on 26 Weeks of Treatment) 
Visit  Target Day  Weight and 
Hematology 
laboratory tests 
Scheduled at Baseline 
and Weeks 6, 10, 14,  
and 26  Chemistry laboratory 
tests and Urinalysis 
laboratory tests 
Scheduled at Baseline 
and Week 26  Serum Creatinine 
and eGFR for MREn 
subjects Scheduled at 
Baseline and Weeks 
22 and 26  Dosing and variables 
Scheduled at Baseline 
and Weeks 2, 6, 14, 
and 22 Vital Signs Scheduled 
at Baseline and 
Weeks 2, 6, 14, 22, 
and 26 Safety Variables by 
Visit 
Visit days are relative to the first dose of open -label medication.  
Baseline 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 
Week 2 15    2 â€“ 28  2 â€’ 28 2 â€’ 28 
Week 6 43 2 â€“ 56   29 â€“ 70 29 â€’ 70 29 â€’ 56 
Week 10 71 57 â€“ 84     57 â€’ 84 
Week 14 99 85 â€“ 140   71 â€“ 126 71 â€’ 126 85 â€’ 126 
Week 22 155   2 â€’ 168 127 â€“ 196 127 â€’ 168  127 â€’ 168  
Final / Week 26  183 141 â€“ 196 2 â€“ 196 169 â€’ 196  169 â€’ 196 169 â€’ 196 
  
 
Page 17 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Table 7.c Visit Analysis Windows for Efficacy Variables Evaluated by Visit (Subjects on 52 Weeks of Treatment) 
Visit  Target Day  CDAI Scheduled at 
Baseline and Weeks 6, 10, 
14,  26, 38, 46 and 52  AVA, Biopsies, and MREn 
Scheduled at Baseline and 
Weeks 26, and 52  C-reactive protein 
Scheduled at Baseline and 
Weeks 10, 26, 38, and 5 2 Ileocolon oscopy Scheduled 
at Baseline and Weeks 14, 
26, and 52  Fecal calpro tectin and 
PRO related QOLs 
Scheduled at Baseline and 
Weeks 14, 26, 38, and 52  
Baseline 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 
Week 2 15      
Week 6 43 2 â€“ 56     
Week 10 71 57 â€“ 84  2 â€’ 126   
Week 14 99 85 â€“ 140   2 â€“ 140 2 â€“ 140 
Week 22 155      
Week 26 183 141 â€“ 224 2 â€“ 232 127 â€’ 224 141 â€“ 232 141 â€“ 224 
Week 30 211      
Week 38 267 225 â€“ 294  225 â€’ 315  225 â€’ 315 
Week 46 323 295 â€“ 343     
Final / Week 52  365 344 â€“ 406 233 â€“ 406 316 â€’ 406 233 â€“ 406 316 â€’ 406 
 
Table 7.d Visit Analysis Windows for Safety Variables Evaluated by Visit (Subjects on 52 Weeks of Treatment) 
Visit  Target Day  Weight 
Scheduled at 
Baseline and 
Weeks 6, 10, 
14, 26, 30, 38, 
46 and 52  Urinalysis 
laboratory tests 
Scheduled at 
Baseline and 
Weeks 26, and 
52 Hematology 
laboratory tests 
Scheduled at 
Baseline and 
Weeks 6, 10, 
14, 26, 38, and 
52 Chemistry 
laboratory tests 
Scheduled at 
Baseline and 
Weeks 26, 38, 
and 52 Serum 
Creatinine  and 
eGFR for 
MREn subjects 
Scheduled at 
Baseline and 
Weeks 22, 26, 
38, 46, and 52  Dosing 
Scheduled at 
Baseline and 
Weeks 2, 6, 14, 
22, 30, 38, and 
46 Vital signs 
Scheduled at 
Baseline and 
Weeks 2, 6, 14, 
22, 26, 30, 38, 
46, and 52  Safety 
Variables by 
Visit 
Visit days are relative to the first dose of open -label medication.  
Baseline 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 â‰¤ 1 
Week 2 15      2 â€“ 28  2 â€“ 28  2 â€’ 28 
Week 6 43 2 â€“ 56  2 â€’ 56   29 â€“ 70 29 â€“ 70 29 â€’ 56 
Week 10 71 57 â€“ 84  57 â€’ 84     57 â€’ 84 
Week 14 99 85 â€“ 140  85 â€’ 140   71 â€“ 126 71 â€“ 126 85 â€’ 126 
Week 22 155     2 â€’ 168 127 â€“ 196 127 â€’ 168  127 â€’ 168  
Week 26 183 141 â€“ 196 2 â€“ 196  141 â€’ 196 2 â€’ 196 169 â€’ 196  169 â€“ 196 169 â€’ 196 
Week 30 211 197 â€’ 238     197 â€“ 238 197 â€“ 238 197 â€’ 231 
Week 38 267 239 â€“ 294  197 â€’ 315 197 â€’ 315 197 â€’ 294 239 â€“ 294 239 â€“ 294 239 â€“ 294 
Week 46 323 295 â€’ 343     295 â€’ 343  295 â€“ 392 295 â€“ 343 295 â€“ 343 
Final / Week 52  365 344 â€“ 392 197 â€“ 392 316 â€’ 392 316 â€’ 392 344 â€’ 392  344 â€“ 392 344 â€“ 392 
 
 
Page 18  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Data identified on the eCRF as coming from the â€œfollow-upâ€ visit (i.e., Postdose 18 Week Safety 
Follow-up) will be summarized as collected and entered. These study visits will not be 
windowed. 
 
The study window convention will not be applied to data listings; the data listings will display 
the visits as collected and entered in the eCRF. 
7.1.6 Convention for Calculation of SES- CD Scores 
The SES-CD has been shown to be comparable to the Crohnâ€™s Disease Endoscopic Index of 
Severity and a straightforward scoring system for Crohnâ€™s disease [ 2]. The overall SES-CD score 
ranges from 0 to 56 and is the sum of 4 variables (i.e., size of ulcers [cm], ulcerated surface [%], 
affected surface [%], and presence of narrowing) across 5 bowel segments (i.e., rectum, 
descending and sigmoid colon, transverse colon, ascending colon, and ileum). Each variable is 
coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is the most severe case, 
with the sum of the scores for each variable ranging from 0 to 15, except for presence of 
narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a 
narrowing which a colonscope cannot be passed and, thus, can only be observed once among the 
bowel segments. The segmental SES-CD score is the sum of the 4 variables for each bowel 
segment and can range from 0 to 12, where each individual variable score ranges from 0 to 3 (see 
Appendix B ). 
7.1.7 Convention for Calculation of CDAI Scores 
The CDAI score is the summation of 8 components, including number of liquid or very soft 
stools, abdominal pain, general well-being, extra-intestinal manifestations of Crohnâ€™s Disease, 
Lomotil/Imodium/opiates for diarrhea usage, abdominal mass, hematocrit level, and body weight 
(see Appendix C ). 
Number of liquid or very soft stools, abdominal pain, and general well-being are self-reported 
via subject electronic diary entries. To calculate subscores at each visit, the diary data from the 
10 days prior to the date of CDAI calculation were used and the following rules were applied: 
1. Take the 7 most recent days of diary data prior to the date of CDAI calculation. If the 
CDAI analysis visit is Screening and less than 7 days of data are present, a subscore 
cannot be calculated. 
2. For number of liquid or very soft stools only, if any of the 7 most recent days of diary 
data have stool frequency values greater than 24, set the value for the stool record for that 
day to missing. 
3. If less than 4 non-missing results remain, the subscore cannot be calculated, and the 
subject will be categorized as a non-responder. Otherwise, calculate the subscore by 
summing the values, dividing by the number of non-missing records included in the 
summation, and multiplying by the factor appropriate for the given subscore. 
a. For stool, the factor is 2. 
b. For abdominal pain, the factor is 5. 
 
Page 19  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 c. For general well-being, the factor is 7. 
Table 7.e provides examples of calculated CDAI scores using various eDiary scenarios 
(excluding eligibility). Table 7.f provides examples of calculated CDAI scores using various 
eDiary scenarios for eligibility. Patient diaries can be completed 14 days prior to the eligibility 
visit. Any on -study colonoscopies and/or MREn are taken into account such that the diary data 
from the day prior, day of, and day after are excluded from the visitâ€™s CDAI calculation. 
Table 7.e Examples of eDiary Subscore Entries and Corresponding Subscore 
De
rivation (Excluding Eligibility) 
Day 
-14 Day 
-13 Day 
-12 Day 
-11 Day 
-10 Day 
-9 Day 
- 8 Day 
-7 Day 
-6 Day 
-5 Day 
-4 Day 
-3 Day 
-2 Day 
-1 Raw 
Sum Final 
Subtotal 
(factor = x 2)  
1 2 M 2 2 2 2 1 1 1 1 1 1 1 7 14 
1 X MRE X 3 X C X 1 1 1 1 1 1 9 18 
1 2 M 2 M 3 M 3 M 3 M 3 3 3 21 42 
1 2 M 2 M 2 M M M 1 3 2 2 M 14 28 
1 M M 2 3 X MRE X X C X 3 3 3 21 42 
1 M X MRE X C X M 2 M M M 2 0 N/A N/A 
M = Missing data. 
C = Colonoscopy. 
N/A = Not Available. 
Used days are highlighted. 
Table 7.f Examples of eDiary Subscore Entries for Eligibility and Corresponding 
S
ubscore Derivation (for Eligibility, only rule #1 applies)  
Day 
-14 Day 
-13 Day 
-12 Day 
-11 Day 
-10 Day 
-9 Day 
- 8 Day 
-7 Day 
-6 Day 
-5 Day 
-4 Day 
-3 Day 
-2 Day 
-1 Raw 
Sum Final 
Subtotal 
(factor = x 2)  
1 2 M 2 2 2 2 1 1 1 1 1 1 1 7 14 
X MRE X 3 3 3 X C X 3 3 3 3 M 21 42 
1 2 M 2 3 3 3 M 1 2 2 3 R 1 17 34 
1 2 M 2 3 3 3 3 2 2 2 R 2 3 18 36 
1 X MRE X 3 X C X 2 2 3 R 3 1 N/A N/A 
2 3 2 2 3 X C X 3 2 2 2 3 3 18 36 
1 3 M M 2 1 2 3 X C X 3 R 2 N/A N/A 
M = Missing data. 
C = Colonoscopy. 
R = Subscore requested. 
N/A = Not Available. 
Used days are highlighted.  
In addition to the subscores originating from the subject electronic diary entries, subscores for 
extra-intestinal manifestations of Crohnâ€™s Disease, usage of Lomotil/Imodium/opiates for 
diarrhea, abdominal mass, hematocrit level, and body weight are calculated. 
Extra-intestinal manifestations of Crohnâ€™s Disease include arthritis/arthralgia, iritis/uveitis, 
erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure fistula, or abscess, 
 
Page 20  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 other fistula, and fever over 37.8 Â°C during the past week. The total number of extra- intestinal 
manifestations is summed and multiplied by a factor of 20. 
If a subject used Lomotil/Imodium/opiates for diarrhea, they have a subscore of 30. Otherwise, 
their usage of Lomotil/Imodium/opiates for diarrhea subscore is 0. 
For a definite, questionable, or no abdominal mass, a subject receives a subscore of 50, 20, or 0, 
respectively. 
Hematocrit results are subtract ed from 47 for males and from 42 for females to obtain the 
hematocrit subtotal. The hematocrit subtotal is then multiplied by a factor of 6 to determine the 
hematocrit subscore. If the hematocrit subtotal is 0, the hematocrit subscore is also 0. 
Lastly, the body weight subscore is obtained with the following formula: 
[1 âˆ’ (Body Weight
Standard Weight)]Ã—100 
where standard weight is calculated as (height in m)2Ã—22.1 for males and (height in m)2Ã—20.8 
for females. If the body weight subscore is < -10, the body weight subscore is set to -10. 
To calculate the total CDAI score for a study visit, sum all 8 component subscores at that 
particular study visit. If any of the 8 subscores are missing, the total CDAI score cannot be 
calculated for that study visit. 
7.1.8 Conventions for Missing Adverse Events Dates 
Every effort will be made to determine the actual onset date for the event or to obtain a reliable 
estimate for the onset date from the investigator. 
For AEs or SAEs, a missing or incomplete onset date will be imputed according to the following 
conventions: 
1. If an onset date is missing, the derived onset date will be calculated as the first non-
missing valid date from the following list (in order of precedence): 
ï‚· First study medication date 
ï‚· Informed consent date (for SAEs only) 
2. If an onset date is incomplete, the derived onset date will be calculated following: 
ï‚· Missing day, but month and year present: the day will be imputed as the 15th of the 
month. If the month and year are equal to the month and year of the first study 
medication dose and the first study medication dose occurs after the imputed date, the 
derived onset date will be set equal to the first study medication date. If the AE end 
date occurs prior to the imputed date, the derived onset date will be set equal to the 
AE end date. 
ï‚· Missing day and month, but year present: the day and month will be imputed as the 
30th June of the year. If the year is equal to the year of the first study medication dose 
and the first study medication dose occurs after the imputed date, the derived onset 
 
Page 21  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 date will be set equal to the first study medication date. If the AE end date occurs 
prior to the imputed date, the derived onset date will be set equal to the AE end date. 
ï‚· If the imputed AE onset date occurs after the database lock date, the imputed AE 
onset date will be imputed as the database lock date. 
For AEs or SAEs, a missing or incomplete end date will be imputed according to the following 
conventions: 
1. If an end date is missing, the derived end date will be imputed as the last assessment date, 
assuming that the last assessment occurs after the AE start. If the last assessment occurs 
prior to the AE start date, the derived end date will be imputed as the AE start date. 
2. If an end date is incomplete, the derived end date will be calculated following:  
ï‚· Missing day, but month and year present: the day will be imputed as the last date (for 
example February 2009 will be imputed as 28 February 2009) of the month. 
ï‚· Missing day and month, but year present: the day and month will be imputed as the 
31st December of the year. 
ï‚· If the imputed AE end date occurs after the database lock date, the imputed AE end 
date will be imputed as the database lock date. 
7.1.9 Conventions for Missing Concomitant Medications Dates 
Start and stop dates for all concomitant medications are collected on the eCRF. However, in case 
of missing or partial information in these dates, the following rules will be used: 
If the start date is missing or partial: 
ï‚· If the day is missing, the start day will be the first day of the month.  
ï‚· If the month is missing, the start month will be the month corresponding to 90 days prior 
to the first study medication date. 
ï‚· If the year is missing, the start year will be the minimum of the year of the first clinic 
visit or the year of the informed consent date. 
ï‚· If the entire date is missing, the start date will be the date of first study drug 
administration.  
If the stop date is missing, partial or â€œcontinuingâ€: 
ï‚· If the day is missing, the stop day will be the last day of the month reported. 
ï‚· If the month is missing, the stop month will be the month during which the last dose of 
treatment was administered. 
ï‚· If the year or the entire date is missing or if the medication is â€œcontinuingâ€, the stop year 
will be the year in which the last dose of treatment was administered. 
7.1.10 Conventions for Missing Previous Medications Dates 
No dates will be imputed for previous medications. 
 
Page 22  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.1.11 Conventions for Calculation of Duration of CD 
Duration of CD is calculated as the number of years from CD diagnosis date to first dose date: 
1 + date first dose âˆ’ date diagnosis
365. 25 
The duration of CD will be included in the baseline CD characteristics listing. If the date CD was 
diagnosed is partially missing, the following rules will take effect: 
ï‚· Missing day, but month and year are present: the day will be imputed as the 15th day of 
the month. 
ï‚· Missing day and month, but year is present: the day and month will be imputed as 30th 
June of the year. 
7.1.12 Calculation of Body Mass Index 
BMI will be calculated as the ratio of patientâ€™s weight (in kilograms) to the square of the 
patientâ€™s height (in meters): 
BMI (kg
m2) =weight (kg)
[height (m)]2 
7.1.13 Methods for Handling of Missing Efficacy Data 
Through the end of the treatment period, the missing efficacy data will be handled as follows: 
ï‚· Missing data for dichotomous (i.e., proportion-based) endpoints will be handled using the 
non-responder imputation method, i.e. any subject with missing information for 
determination of endpoint status will be considered as a non-responder in the analysis.  
ï‚· Missing data for continuous endpoints will be imputed using last available post-baseline 
observation carried forward (LOCF) method. 
7.2 A NALYSIS SETS 
 The Study Part A analyses will be performed on the following analysis sets: 
ï‚· The Full Analysis Set (FAS) will include all enrolled subjects who receive at least 1 dose 
of study drug. 
ï‚· The FAS-MREn is the FAS within the MREn substudy. 
ï‚· The Per Protocol Analysis Set (PPS) is a subset of the FAS and consists of all subjects 
who do not violate the terms of the protocol in a way that would impact the study 
outcome significantly. Major protocol violations that exclude a subject from the PPS are 
listed in Section 7.4. Efficacy analyses for the primary and secondary endpoints using the 
PPS population may be provided as part of a sensitivity analysis. 
ï‚· The PPS-MREn is a subset of the FAS-MREn and consists of all subjects who do not 
violate the terms of the protocol in a way that would impact the study outcome 
significantly. Major protocol violations that exclude a subject from the PPS-MREn are 
 
Page 23  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 listed in Section 7.4. Efficacy analyses for the MREn endpoints using the PPS-MREn 
population may be provided as part of a sensitivity analysis. 
The Study Part B analyses will performed on the following analysis sets: 
ï‚· The FAS-Extension is the subset of subjects in the FAS who consented to Part B. 
ï‚· The FAS-MREn-Extension is the subset of subjects in the FAS-MREn who consented to 
Part B. 
ï‚· The PPS-Extension is the subset of subjects in the FAS-Extension and consists of all 
subjects who do not violate the terms of the protocol in a way that would impact the 
study outcome significantly. Major protocol violations that exclude a subject from the 
PPS-Extension are listed in Section 7.4. Efficacy analysis for the primary and secondary 
endpoints using the PPS-Extension population may be provided as part of a sensitivity 
analysis. 
ï‚· The PPS-MREn-Extension is the subset of subjects in the FAS-MREn -Extension and 
consists of all subjects who do not violate the terms of the protocol in a way that would 
impact the study outcome significantly. Major protocol violations that exclude a subject 
from the PPS-MREn-Extension are listed in Section 7.4. Efficacy analysis for the MREn 
endpoints using the PPS-MREn-Extension population may be provided as part of a 
sensitivity analysis. 
The FAS and FAS-Extension will be used in both efficacy and safety analyses. The FAS-MREn 
and FAS-MREn-Extension will be used in the MREn analyses. Analyses using PPS,  PPS-
Extension, PPS-MREn, and PPS-MREn-Extension populations may be provided as sensitivity 
analyses.  
Sensitivity analyses for the primary and secondary efficacy endpoints using PPS/PPS-Extension 
will be conducted only if more than 15% of the subjects in the FAS/FAS-Extension have at least 
1 significant protocol deviation. 
7.3 D ISPOSITION OF SUBJECTS 
Disposition will be evaluated for the following study periods: screening and treatment period.  
Disposition of all screened subjects (denominator) will be tabulated (count and percent).  
Disposition of screen failures (denominator) will be tabulated according to primary screen failure 
reason (e.g.,  pretreatment event, major protocol deviation, lost to follow-up, etc.) as entered on 
the eCRF. 
Disposition of all enrolled subjects will be tabulated as :  
ï‚· All enrolled subjects (denominator)  
ï‚· Subjects who were enrolled but not treated, if applicable  
ï‚· All subjects who completed the study drug/visits 
ï‚· All subjects who prematurely discontinued (permanently) study drug/visits 
 
Page 24  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Primary reasons for discontinuation of study drug/visits, as entered on the eCRF, will be 
tabulated; the reasons include adverse event, significant protocol deviation, lost to follow-up, 
voluntary withdrawal, study termination, pregnancy, lack of efficacy and other.  
Disposition of enrolled subjects by analysis set will be also tabulated.  
The date of first dose, date of last dose, duration of treatment and the reason for premature 
discontinuation of study drug/study visit will be listed for each enrolled subject. A listing of 
inclusion/exclusion criteria responses by subject will also be provided. A separate listing of 
screen failures and criteria will be presented.  
Study information, including date first subject signed ICF, date of last subjectâ€™s last visit/contact, 
date of last subjectâ€™s last procedure for collection of data for primary endpoint, Medical 
Dictionary for Regulatory Activities (MedDRA) v ersion, World Health Organization Drug 
Dictionary (WHODrug) v ersion, and SAS Version will be presented. 
Summary of eligibility from entrance into the treatment phase will be tabulated and listed. 
The enrolled subjects who did not meet at least one inclusion criteria or who did meet at least 
one exclusion criteria will be listed. 
The number of subjects enrolled by site will be tabulated and listed. 
7.4 M AJOR P ROTOCOL VIOLATIONS  
Major protocol violations used to exclude subjects from the PPS population include: 
1. A missing Week 26 ileocolonoscopy. 
2. An Entry Criteria significant protocol deviation. 
Additional major protocol violations for exclusion from the PPS population may be finalized as 
part of a final data review and documented prior to database lock. 
Major protocol violations used to exclude subjects from the PPS-Extension population include: 
1. A missing Week 52 ileocolonoscopy. 
2. An Entry Criteria significant protocol deviation. 
Additional major protocol violations for exclusion from the PPS-Extension population may be 
finalized as part of a final data review and documented prior to database lock. 
Major protocol violations used to exclude subjects from the PPS-MREn population include: 
1. Missing numeric scores in more than 3 ileocolonic bowel segments at both Baseline and 
Week 26.  
Major protocol violations used to exclude subjects from the PPS-MREn-Extension population 
include: 
1. Missing numeric scores in more than 3 ileocolonic bowel segments at both Baseline and 
Week 52. 
All major protocol violations will be tabulated and listed. 
 
Page 25  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.5 S IGNIFICANT PROTOCOL DEVIATIONS  
Significant p rotocol deviations will be collected onto the eCRF throughout the conduct of the 
study. Significant deviations will be tabulated using the following categories: 
ï‚· Entry Criteria 
ï‚· Concomitant Medication 
ï‚· Procedures Not Performed Per Protocol (Primary Endpoint or Safety Related) 
ï‚· Study Medication 
ï‚· Withdrawal Criteria 
Significant p rotocol deviations will be also listed by subject. 
7.6 D EMOGRAPHIC AND BASELINE CHARACTERISTICS  
Table 7.g lists the variables which will be tabulated in the demographic and baseline 
characteristics table for enrolled subjects. 
Table 7.g  Summaries of Demographic and Baseline Characteristics  
Demography (unit)  Summarized as  Categories  
Age (years)  Continuous and 
Categorical  <35, â‰¥ 35  
<65, â‰¥ 65  
<75, â‰¥ 75  
Gender Categorical  Male 
Female 
Racea Categorical  American Indian or Alaska Native  
Asian 
Black or African American  
Native Hawaiian or Other Pacific Islander  
White 
Ethnicity Categorical  Hispanic or Latino  
Non-Hispanic and Latino  
Height (cm)  Continuous   
Weight (kg) Continuous   
Body Mass Index ( BMI) (kg/m2) Continuous   
Smoking Classification  Categorical  Subject has never smoked  
Subject is a current smoker  
Subject is an ex -smoker 
Female Reproductive Status  Categorical  Postmenopausal  
Surgically Sterile  
Female of Childbearing Potential 
N/A (Subject is a Male)  
a recorded on the eCRF. Subjects who identify themselves as more than one race on the eCRF will be classified as Multiracial 
for tabulation, and will be included only in the Multiracial category. 
Screen failures will be tabulated and listed for age, age group, gender, ethnicity and race. All 
other demographic and baseline characteristic summaries will be tabulated and listed using the 
FAS, the FAS-Extension, the FAS-MREn, and the FAS-MREn -Extension. In addition, original 
read MREn parameters (i.e., image adequacy, adequacy reason, relative contrast enhancement, 
 
Page 26  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 wall thickness, ulceration, edema, global MaRIA score, segmental MaRIA score, presence of 
fistulas, fistulas description, presence of obstructive lesions, fluid collections, fluid collection 
change, inflammatory mass, and inflammatory mass change) at the Screening visit for screen 
failures at the selected MREn substudy centers will be summarized for each ileocolonic segment 
and more proximal bowel segments, if evaluable, using the FAS-MREn and the FAS-MREn-
Extension.  Ileocolonic bowel segments include the ascending colon, descending colon, 
transverse colon, sigmoid colon, rectum, and terminal ileum. Proximal bowel segments include 
the jejunum J-1, jejunum J-2, proximal ileum PI-1, and proximal ileum PI-2.  
Table 7.h lists the CD -related baseline characteristics which will be tabulated and listed. 
Table 7.h Summaries of CD-Related Baseline Characteristics  
Characteristics (unit)  Summarized as  Categories  
Duration of C rohnâ€™s Disease (years) Continuous  and 
Categorical  < 1 year 
â‰¥ 1 to < 3 years  
â‰¥ 3 to < 7 years  
â‰¥ 7 years 
Baseline CRP (mg/L)  Continuous  and 
Categorical  â‰¤ 2.87 mg/L  
> 2.87 mg/L â‰¤ 5 mg/L  
> 5 mg/L â‰¤ 10 mg/L  
> 10 mg/L  
Elevated baseline CRP (mg/L)  Continuous  and 
Categorical  Yes (CRP > 2.87 mg/L)  
No  (CRP â‰¤ 2.87 mg/L)  
Concomitant use of oral corticosteroids  Categorical  Yes 
No 
Prior TNF -alpha status Categorical  NaÃ¯ve 
Failure 
Baseline Fecal Calprote ctin (Âµg/g) Continuous  and 
Categorical  â‰¤ 250 Âµg/g 
> 250 Âµg/g â‰¤ 500 Âµg/g 
> 500 Âµg/g 
Baseline CDAI Activity  Continuous  and 
Categorical  â‰¤ 330 
> 330 
Baseline SES -CD Score  Continuous  and 
Categorical  <7 
7-15 (moderate)  
>15 (severe)  
In addition, Baseline MREn parameters for enrolled subjects at the selected MREn substudy 
centers will be summarized for each ileocolonic segment and more proximal bowel segments, if 
evaluable, using the FAS-MREn and the FAS-MREn-Extension. 
All individual demographic and baseline characteristics will be listed by region, site, and subject 
number. 
7.7 M EDICAL HISTORY AND CONCURRENT MEDICAL CONDITIONS  
Summaries of medical history, defined as significant conditions or diseases that stopped at or 
prior to the time of informed consent, and concurrent medical conditions, defined as significant 
ongoing conditions or diseases present at signing of informed consent, will be summarized based 
on the FAS.  
 
Page 27  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Medical history and concurrent medical conditions will be coded using the MedDRA (Version 
19 or higher) coding system. Medical history and concurrent medical conditions will be 
summarized by system organ class (SOC) and preferred term (PT). The tables will be sorted in 
alphabetic order by SOC and in decreasing frequency based on the total number of reports by 
preferred terms in each SOC. The number and percentage of subjects with any significant 
medical history and concurrent medical conditions will be summarized for each SOC and 
preferred term. The denominator used for calculating the percentages will be the total number of 
subjects. For the tables, if a subject reports the same preferred term multiple times, then that 
preferred term will be counted only once for that subject. Similarly, if a subject reports multiple 
conditions within the same SOC, then that SOC will be counted only once for that subject in the 
tables.  
All medical history and concurrent medical condition data will be listed by site and subject 
number. The listing will contain subject identifier, treatment, SOC, PT, whether there was any 
medical history or concurrent condition, and if yes, a detail of the medical history or concurrent 
condition. 
7.8 M EDICATION HISTORY AND CONCOMITANT MEDICATIONS  
Summaries of medication history and concomitant medications will be tabulated based on the 
FAS.  
Medication history information to be obtained and recorded on the eCRF includes any 
medication relevant to eligibility criteria that stopped at or within 30 days prior to signing of 
informed consent. The CD prior biologic medication which have been stopped are recorded on 
the eCRF as well. 
Concomitant medications are recorded on the eCRF and include any medication other than study 
drug taken at any time between the times of informed consent through the end of the study. Any 
ongoing CD biologic medications are included with the Concomitant Medications.   
Medication history, CD prior biologic medications,  and concomitant medications will be coded 
using the WHODrug dictionary (Version 01March 2015 or higher).  
Concomitant medications will be summarized by therapeutic classification and preferred 
medication name and will include only those medications taken at any time between the times of 
informed consent and on or prior to the last dose date of study drug. Concomitant medications 
will be classified and summarized separately as follows:  
ï‚· Concomitant medications that started and stopped prior to baseline: any medication 
stopped after time of informed consent and prior to the first dose of the study medication.  
ï‚· Concomitant medications that started prior to and were ongoing at baseline: any 
medication that started before and was not stopped prior to the first dose of the study 
medication.  
ï‚· Concomitant medications that started after baseline: any medication that started at or after 
the first dose of the study medication.  
 
Page 28  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Concomitant medications that were ongoing and  started after baseline: any medication 
that started before and was not stopped prior to the first dose of the study medication or 
any medication that started at or after the first dose of the study medication. 
The tables for medication history and  CD prior biologic medications will present the number and 
percentage of subjects by preferred medication name using the total number of subjects in the 
treatment arm as the denominator. Preferred medication names are sorted by decreasing 
frequency based on the total number of subjects. 
Separate listings for medication history, CD prior biologic medications, and concomitant 
medications will be produced by site and subject number. The listing for medication history will 
contain site number, subject number, treatment, WHODrug preferred medication name, dose, 
frequency, unit, route, end date, and whether the medication was ongoing. The listing for CD 
prior biologics medications which have been stopped will contain site number, subject number, 
treatment,  WHODrug preferred medication name, dose, unit, frequency, route, start date, end 
date, reason for discontinuation, and primary reason for intolerance. The listing for concomitant 
medication will contain site number, subject number, treatment, WHODrug preferred medication 
name, dose, unit, frequency, route, start date, end date, study day, and whether the medication 
was given to treat PTE/AE. 
7.9 S TUDY DRUG EXPOSURE AND COMPLIANCE  
Study drug exposure will be summarized based on the FAS and the FAS-Extension.  
Exposure will be presented as the frequency and percentage of subjects who received complete 
infusions. A subject has received complete infusion if the total amount was infused as per data 
collected in eCRF.  
Duration of exposure will be calculated as (date of last dose â€“  date of first dose) + 127. Duration 
of exposure will be summarized continuously and categorically. For Study Part A, duration of 
exposure will be summarized in the following categories : <20 Weeks, 20 â€“ <24 Weeks, 24 - <32 
Weeks, 32  â€“ <40 Weeks, and â‰¥ 40  Weeks. For Study Part B, duration of exposure will be 
summarized in the following categories: <56 Weeks, 56  - <64 Weeks, and â‰¥ 64  Weeks. 
Since all doses will be administered at in-clinic visits compliance will not be presented.  
All study drug administration and accountability data will be listed by site and subject number. 
The following variables will be listed: subject number, treatment, dose dates and times, dose 
interruption dates and times (if applicable), and completion status of infusion and reason for 
incomplete infusion.  
7.10 E FFICACY ANALYSIS 
This section describes the analyses to be conducted on the primary, secondary,  and additional 
efficacy endpoints. 
All proportion-based efficacy endpoints will be summarized by presenting the point estimate and 
2-sided 95% confidence intervals (CIs) for the proportion. All subjects with missing data for 
determination of endpoint status will be considered as a non-responder in the analysis.  
 
Page 29  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 All change from Baseline-based efficacy endpoints will be summarized descriptively by time 
point for observed and change from Baseline values. Missing data will be imputed using the 
LOCF method. 
7.10.1 Primary Efficacy Endpoint 
Primary efficacy analysis will be summarized based on the FAS.  
The primary endpoint is the proportion of subjects achieving endoscopic remission, defined as a 
total SES-CD score of â‰¤ 4 at Week 26. The proportion of subjects with endoscopic remission and 
its 2-sided 95% CI  will be calculated using the Clopper-Pearson method.  
Subjects with a missing SES-CD score at Week 26 will be considered as non-responders.   
All SES-CD score components will be listed by site and subject number for each bowel segment. 
7.10.1.1 Sensitivity Analyses for Primary Efficacy Endpoint 
To assess the robustness of the primary efficacy analysis, the following additional analyses will 
be performed for the primary endpoint. 
ï‚· The proportion of subjects with endoscopic remission and its 2-sided 95% CI will be 
calculated excluding subjects with a Screening SES-CD score <7.  
ï‚· The proportion of subjects with endoscopic remission and its 2-sided 95% CI will be 
calculated using the PPS (if applicable). 
ï‚· The proportion of subjects with endoscopic remission and its 2-sided 95% CI will be 
calculated using the LOCF method. 
7.10.1.2 Summaries of Primary Efficacy Endpoint within Subgroups 
The primary efficacy endpoint of endoscopic remission will be summarized for the following 
subgroups using the FAS, and the PPS (if applicable): 
ï‚· Baseline Disease Activity (CDAI) ( â‰¤330, > 330) 
ï‚· Duration of CD (<1 year, 1 â€“ <3 years, 3 â€“  <7 years, â‰¥7 years) 
ï‚· Geographic Region (North America, Western / Northern Europe, Central Europe, Eastern 
Europe, Africa / Asia / Australia) 
ï‚· Baseline CRP ( â‰¤5 mg/L, >5 mg/L; â‰¤10 mg/L, >10 mg/L) 
ï‚· Baseline Fecal Calprotectin (â‰¤250 Î¼g/g, >250 Î¼g/g; â‰¤500 Î¼g/g, >500 Î¼g/g) 
ï‚· Prior TNF-alpha Status (NaÃ¯ve, Failure) 
ï‚· Baseline SES-CD (<7, 7 to 15 (Moderate), >15 (Severe)) 
7.10.2 Secondary Efficacy Endpoints 
 
Page 30  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Secondary efficacy analyses will be summarized based on the FAS and FAS-Extension. 
Subgroup analyses will be performed using prior TNF-alpha status (naÃ¯ve, failure). 
Descriptive statistics (N, mean, SD, median, minimum, and maximum) for the observed and 
change from baseline values for the segmental SES-CD scores, the overall SES-CD score, and 
the CDAI score will be presented. 
The details collected on each of the below endpoints will be listed. 
7.10.2.1  Complete Mucosal Healing 
The proportions of subjects with ulcerations at Baseline who achieve complete mucosal healing 
at Week 26 and Week 52 and their 2-sided 95% CI will be calculated. Complete mucosal healing 
is defined as the absence of ulceration, which is demarcated as an SES-CD variable â€˜Size of 
Ulcersâ€™ score of 0 ( Appendix B ), from the presence of ulceration at Baseline. Subjects with any 
missing â€™Size of Ulcersâ€™ score at Week 26 or Week 52 will be considered as non-responders. 
Complete mucosal healing will also be summarized for the subgroups listed in section 7.10.1.2 
based on the FAS, FAS-Extension, PPS, and PPS-Extension. 
7.10.2.2 Endoscopic Remission  
Endoscopic remission at Week 14 and Week 52 will be analyzed following a similar approach 
outlined in section 7.10.1. 
7.10.2.3 Endoscopic Response 
The proportions of subjects with endoscopic response (defined as SES-CD reduction by at  least 
50% from baseline) at Week 14 , Week 26, and Week 52 and their CIs will be calculated by 
bowel segment and overall. Subjects with a missing SES-CD at Week 14, Week 26, and/or Week 
52 will be considered as non-responders.  A sensitivity analysis will be performed for the 
proportion of subjects with endoscopic response and its 2-sided 95% CI using the LOCF method. 
Analyses for endoscopic response will also be performed overall and by prior TNF-alpha status 
(naÃ¯ve, failure) based on the PPS and PPS-Extension. 
7.10.2.4 Clinical Response 
The proportions of subjects achieving clinical response (CDAI score decrease from baseline of at 
least 100 points ) at Week 10, Week 26 , and Week 52  and their CIs will be calculated. Subjects 
with a missing CDAI score at Week 10, Week 26, and/or Week 52 will be considered as non-
responders. 
Analyses for clinical response will also be performed overall and by prior TNF-alpha status 
(naÃ¯ve, failure) based on the PPS and PPS-Extension. 
  
 
Page 31  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.10.2.5  Clinical Remission 
The proportions of subjects achieving clinical remission (CDAI score of at most 150) at Week 
10, Week 26, and Week 52 and their CIs will be calculated.  Subjects with a missing CDAI score 
at Week 10,  Week 26, and/or Week 52 will be considered as non-responders. 
Analyses for clinical remission will also be performed overall and by prior TNF-alpha status 
(naÃ¯ve, failure) based on the PPS-Extension. 
7.10.2.6 Durable Clinical Remission 
The proportion of subjects in Study Part B with durable clinical remission (defined as clinical 
remission at Week 26 and Week 52) at Week 52 and its CI will be calculated. Subjects with a 
missing CDAI score at Week 52 will be considered as non-responders. 
Analyses for durable clinical remission will also be performed overall and by prior TNF-alpha 
status (naÃ¯ve, failure) based on the PPS-Extension. 
7.10.3 Additional Efficacy Endpoints 
Additional efficacy analyses will be summarized based on the FAS, FAS-Extension, FAS-
MREn, and FAS-MREn-Extension, as applicable. Subgroup analyses will be performed using 
prior TNF-alpha status (naÃ¯ve, failure). 
Descriptive statistics (N, mean, SD, median, minimum, and maximum) for the observed and 
change from baseline values for the ileal, colonic, and total Global Histological Disease Activity 
Scores (GHAS) will be presented. 
The correlation between subjectsâ€™ SES-CD scores and MaRIA scores by study visit will be 
explored by bowel segment and overall using scatter plots. The correlation between subjectsâ€™ 
CDAI score and global MaRIA score by study visit will be explored using scatter plots. 
The relationship between the various remission statuses, as defined by CDAI (i.e., clinical 
response and clinical remission), endoscopic (i.e., endoscopic response, endoscopic remission, 
and complete mucosal healing), imaging (i.e., ileocolonic remission by MREn, overall remission 
by MREn, ileocolonic response by MREn, and overall response by MREn), and histological (i.e., 
total GHAS â‰¤ 4 ) assessments, will also be explored using Pearsonâ€™s correlation coefficient in the 
following combinations:  
ï‚· Clinical Response and Endoscopic Response 
ï‚· Clinical Response and Endoscopic Remission 
ï‚· Clinical Response and Ileocolonic Remission by MREn 
ï‚· Clinical Response and Overall Remission by MREn 
ï‚· Clinical Response and Total GHAS â‰¤ 4 
ï‚· Clinical Remission and Endoscopic Response 
ï‚· Clinical Remission and Endoscopic Remission 
 
Page 32  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Clinical Remission and Ileocolonic Remission by MREn 
ï‚· Clinical Remission and Overall Remission by MREn 
ï‚· Clinical Remission and Total GHAS â‰¤ 4 
ï‚· Endoscopic Response and Ileocolonic Remission by MREn 
ï‚· Endoscopic Response and Overall Remission by MREn 
ï‚· Endoscopic Response and Total GHAS â‰¤ 4 
ï‚· Endoscopic Remission and Ileocolonic Remission by MREn 
ï‚· Endoscopic Remission and Overall Remission by MREn 
ï‚· Endoscopic Remission and Total GHAS â‰¤ 4 
ï‚· Complete Mucosal Healing and Ileocolonic Remission by MREn 
ï‚· Complete Musocal Healing and Ileocolonic Response by MREn 
ï‚· Ileocolonic Remission by MREn and Total GHAS â‰¤ 4 
ï‚· Overall Remission by MREn and Total GHAS â‰¤ 4 
The correlation between subjectsâ€™ change from Baseline in CDAI, change from Baseline in SES-
CD, change from Baseline in MaRIA, and change from Baseline in GHAS by study visit will be 
explored using scatter plots. 
The details collected on each of the below endpoints will be listed. 
7.10.3.1  MREn Parameters 
Only original read MREn parameters will be utilized for analyses. 
Continuous individual MREn parameters (i.e., relative contrast enhancement, wall thickness, 
global MaRIA score, and segmental MaRIA score) for each ileocolonic segment (i.e., ascending 
colon, transverse colon, descending colon, sigmoid colon, rectum, and terminal ileum) and more 
proximal bowel segments (i.e., jejunum J-1, jejunum J-2, proximal ileum PI-1, and proximal 
ileum PI-2), if evaluable, will be summarized descriptively at Baseline, each post-Baseline visit, 
and change from Baseline to each post-Baseline visit. 
Shifts in categorical individual MREn parameters (i.e., ulceration, edema, presence of fistulas, 
fistulas description, presence of obstructive lesions, fluid collections, fluid collection change, 
inflammatory mass, and inflammatory mass change ) between baseline and each post-baseline 
visit for each ileocolonic segment and more proximal bowel segments, if evaluable, will be 
presented as cross-tabulations of responses with missing, if applicable, and total categories. 
Scheduled visits for MREn are at Baseline, Week 26, and Week 52. 
Missing data will not be imputed. Original read and re-read MREn parameters will be listed. 
  
 
Page 33  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.10.3.2  MaRIA Scores 
The proportions of subjects achieving segmental MaRIA score <7 at Baseline, Week 26,  and 
Week 52 and their CIs will be calculated.  The proportions of subjects achieving segmental 
MaRIA score <11 will be calculated similarly. In addition, the proportion of subjects achieving 
ileocolonic remission and response by MREn and overall remission and response by MREn at 
Baseline, Week 26, and Week 52 and their CIs will be calculated. The MREn-based measures of 
interest are defined as follows: 
ï‚· Ileocolonic remission is defined as a post-Baseline segmental MaRIA score <7 in every 
ileocolonic segment from a Baseline segmental MaRIA score â‰¥7 in any ileocolonic 
segment. 
ï‚· Overall remission is defined as a post-Baseline segmental MaRIA score <7 in every 
segment, whether ileocolonic or proximal, from a Baseline segmental MaRIA score â‰¥7 in 
any segment.  
ï‚· Ileocolonic response is defined as a post-Baseline segmental MaRIA score <11 in every 
ileocolonic segment from a Baseline segmental MaRIA score â‰¥11 in any ileocolonic 
segment. 
ï‚· Overall response is defined as a post-Baseline segmental MaRIA score <11 in every 
segment, whether ileocolonic or proximal, from a Baseline segmental MaRIA score â‰¥11 
in any segment.  
The proportion of subjects with 25%, 50%, and 75% reduction in ileocolonic MaRIA score at 
Week 26 and Week 52 and their CIs will be calculated by ileocolonic bowel segment. 
In addition, the correlation between the SES-CD size of ulcers parameter and the MaRIA 
ulceration parameter (Yes/No) at Baseline, Week 26, and Week 52 will be explored by bowel 
segment using the chi-squared test. For comparison purposes between SES- CD, GHAS, and 
MaRIA, the following assumptions will be taken: 
ï‚· The SES-CD size of ulcers parameter will be dichotomized with â€˜Noneâ€™ and â€˜Aphthous 
ulcersâ€™ as â€˜Aphthous or Noneâ€™ and â€˜Large ulcersâ€™ and â€˜Very large ulcersâ€™ as â€˜Ulcers > 0.5 
cmâ€™
. 
ï‚· The MaRIA ulceration parameter for the descending colon and sigmoid colon will be 
combined into â€˜descending and sigmoid colonâ€™, where a â€˜Noâ€™ response requires a lack of 
ulceration in both the descending colon and the sigmoid colon. 
ï‚· The MaRIA scores for the descending colon and sigmoid colon will be added together to 
create â€˜descending and sigmoid colonâ€™ for continuous comparisons. 
7.10.3.3 SES-CD Score Reduction 
The proportions of subjects with 25% and 75% reduction of SES-CD at Week 14, Week 26, and 
Week 52 and their CIs will be calculated by bowel segment and overall. 
  
 
Page 34  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.10.3.4  Granulocyte Presence 
The proportion of subjects with no granulocytes present in  the bowel biopsy at Baseline, Week 
26, and Week 52 and their CIs will be calculated. The presence of granulocytes is defined by the 
presence of lamina propria neutrophils and/or neutrophils in the epithelium, which are described 
in Section 7.10.3.5. In addition, the proportion of subjects with no granulocytes present in the 
bowel biopsy at Week 26 and Week 52 will be presented for subjects with granulocytes present 
at Baseline. 
7.10.3.5 Histology Change 
Histology parameters, classified as features of chronicity or features of activity, are given a score 
by a pathologist as follows: 
Classification  Parameter  Score  
Features of Chronicity  
 Structural ( Architectural) Change 0 None 
 1 Not severe  
 2 Severe 
Chronic Inflammatory Infiltrate 0 None 
 1 Increased but not very dense infiltrate  
 2 Very dense infiltrate  
Features of Activity  Lamina Propria Neutrophils  0 None 
 1 Some but not readily detectable  
 2 Easily detectable at low magnification  
Neutrophils in Epithelium  0 None 
 1 In surface epithelium  
 2 In crypt epithelium, with or without 
abscesses  
Epithelial Damage  0 None 
 1 Some degenerative or regenerative 
changes, less than half of epithelium, 
irrespective of surface or crypts  
 2 Some degenerative or regenerative 
changes, more than half of epithelium, 
irrespective of surface or crypts  
Erosion or Ulceration 0 None 
 1 Strictly defined by the presence of 
granulation tissue  
Epithelioid Granuloma  0 None 
 1 Present 
The modified GHAS is calculated as the sum of all individual scores for each parameter listed 
above, for each individual biopsy [ 4]. The features of chronicity GHAS, features of activity 
GHAS, and total segmental GHAS will be calculated for each bowel segment using the highest 
total score in that segment. The ileal GHAS (IGHAS) is defined as the segmental GHAS for the 
ileum. The colonic GHAS (CGHAS) is defined as the highest segmental GHAS amongst the 
rectum, descending/sigmoid colon, transverse colon, and ascending colon. The features of 
chronicity score ranges between 0 and  4, and the features of activity score ranges between 0 and 
8. The IGHAS, CGHAS, and segmental GHAS range between 0 and 12. 
 
Page 35  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 The proportions of subjects meeting the following criteria will be presented: 
ï‚· IGHAS â‰¤ 4 at Baseline, Week 26, and Week 52 and their CIs 
ï‚· CGHAS â‰¤ 4 at Baseline, Week 26, and Week 52 and their CIs 
ï‚· Both IGHAS and CGHAS â‰¤ 4 at Baseline, Week 26, and Week 52 and their CIs 
The proportions listed above will also be presented for subjects who had a modified GHAS score 
> 4 at Baseline. 
The proportions of subjects with an IGHAS or CGHAS â‰¤ 4 and no neutrophils, defined as no 
lamina propria
 neutrophils and no neutrophils in the epithelium, at Baseline, Week 26, and Week 
52 and their CIs will be calculated. Also, the proportions of subjects with an IGHAS or CGHAS 
â‰¤ 4 and no neutrophils at Week 26 and Week 52 will be presented for subjects with a modified 
GHAS score > 4 or neutrophils at Baseline. 
Change from baseline in features of chronicity GHAS, features of activity GHAS, total 
segmental GHAS, and CGHAS will be presented using descriptive statistics. 
7.10.3.6  Normalization of CRP 
The proportions of subjects with elevated CRP at Baseline (CRP > 2.87 mg/L ) who achieve 
normalization of CRP (CRP â‰¤ 2.87 mg/L) at Week 10, Week 26, Week 38, and Week 52 and 
their CIs will be calculated. 
CRP results will be summarized at Baseline, each post-Baseline visit, and change from Baseline 
to each post-Baseline visit. Scheduled visits collection for CRP are at Baseline, Week 10, Week 
26, Week 38, and Week 52. 
7.10.3.7 Fecal Calprotectin 
Fecal calprotectin results from stool samples will be summarized at Baseline, each post-Baseline 
visit, and change from Baseline to each post-Baseline visit. Scheduled visits for stool sample 
collection for fecal calprotectin evaluation are at Baseline, Week 14, Week 26, Week 38, and 
Week 52. 
7.10.3.8 Positive for AVA 
A positive AVA subject is defined as a subject who has at least 1 positive AVA result in any 
postbaseline sample. The proportions of subjects positive for AVA at Baseline, Week 26, Week 
52, and the Postdose 18 Week Safety Follow-up Visit and their CIs will be calculated. 
7.10.3.9 Positive Neutralizing AVA 
A positive neutralizing AVA is defined as a sample that was evaluated as positive in the 
neutralizing AVA assay. The proportions of subjects with positive neutralizing AVA at Baseline, 
Week 26, Week 52, and the Postdose 18 Week Safety Follow-up Visit and their CIs will be 
calculated. 
 
Page 36  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.10.3.10  Clinical Response 
Clinical response at Week 38 and Week 46 will be analyzed following a similar approach 
outlined in section 7.10.2.4. 
7.10.3.11 Clinical Remission 
Clinical remission at Week 38 and Week 46 will be analyzed following a similar approach 
outlined in section 7.10.2.5. 
7.10.3.12 Corticosteroid-Free Remission 
The proportion s of subjects with any corticosteroid use at Baseline who discontinue all 
corticosteroids by Week 10, Week 14, Week 26, and Week 52 and their CIs will be calculated. 
The proportions of subjects with corticosteroid-free remission at Week 10, Week 14, Week 26, 
and Week 52 and their CIs will be calculated. Corticosteroid-free remission is defined as the 
achievement of clinical remission with the discontinuation of corticosteroid use post-Baseline 
from the use of corticosteroids at Baseline. 
7.11 P HARMACOKINETIC /PHARMACODYNAMIC ANALYSIS 
There is no pharmacokinetic or pharmacodynamic analysis planned for this study. 
7.12 O THER OUTCOMES  
The patient reported outcomes (PRO ) analysis includes the change from baseline in QOL 
measures that will be summarized descriptively overall and by endoscopic remission status. 
Subjects will complete the IBDQ, EQ-5D, and WPAI- CD health related QOL questionnaires at 
Baseline, Week 14, Week 26, Week 38, and Week 52. The QOL questionnaires will be 
summarized at Baseline, each post-Baseline visit, and change from Baseline to each post-
Baseline visit. Missing data will be imputed using the LOCF method. 
Derivation guidelines for IBDQ, EQ-5D, and WPAI-CD are documented in Appendix G  of the 
SAP. 
The responses collected on each of the QOL questionnaires will be listed. 
7.12.1 IBDQ 
The IBDQ is a valid and reliable instrument used to assess quality of life in adult patients with 
IBD. It includes 32 questions on 4 domains of health-related quality of life (HRQOL): Bowel 
Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic 
Function (5 items). Patients are asked to recall symptoms and quality of life from the last 2 
weeks and rate each item on a 7-point Likert scale (higher scores equate to higher quality of life). 
A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score 
ranges from 32 to 224. 
  
 
Page 37  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.12.2 EQ-5D Questionnaire 
The EQ-5D questionnaire, developed by EuroQol, is a simple, valid, and reliable instrument used 
to measure general health-related quality of life in patients and includes five domain items - 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Patients choose the 
level of health problems they currently have on each item as â€œNoneâ€, â€œModerateâ€, or â€œExtremeâ€ 
and are scored a 1, 2, or 3, respectively. A composite EQ-5D score can be calculated from the 
individual scores to assess overall HRQOL. The EQ-5D VAS score is a self-assigned rating of 
overall health using a 20 cm visual, vertical scale, with a score of 0 as the worst and 100 as best 
possible health. The EQ-5D total score and EQ-5D VAS score have been shown in many studies 
to be valid and reliable instruments for measuring HRQOL in patients with GI diseases. 
7.12.3 WPAI-CD 
The WPAI questionnaire is a valid and reliable 6-item instrument that consists of four metrics: 
absenteeism (the percentage of work time missed because of oneâ€™s health in the past seven days), 
presenteeism (the percentage of impairment experienced while at work in the past seven days 
because of oneâ€™s health), overall work productivity loss (an overall impairment estimate that is a 
combination of absenteeism and presenteeism), and activity impairment (the percentage of 
impairment in daily activities because of oneâ€™s health in the past seven days). WPAI outcomes 
are expressed as impairment percentages, with higher numbers indicating greater impairment and 
less productivity, i.e., worse outcomes. WPAI-CD is the specific disease version of the 
questionnaire for Crohnâ€™s Disease. 
7.13 S AFETY ANALYSIS 
Safety analyses include AEs, clinical laboratory values, vital signs, and ECGs. All safety 
summaries will be based on the FAS and FAS-Extension. The analysis of safety data will be 
restricted to descriptive statistics only,  unless otherwise specified.  
7.13.1 Adverse Events 
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study, but prior to administration of any study 
medication; it does not necessarily have to have a causal relationship with study participation.  
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this 
treatment. Pretreatment events and AEs will be coded using MedDRA Version 19 or higher. AEs 
will be summarized using the MedDRA SOC, high level term (HLT),  and PT. 
Treatment-emergent adverse events (TEAEs) will be defined as any AE that occurs after the first 
dose of study drug and up to the last dose or early termination plus applicable follow up (i.e., 18 
weeks). 
If the onset date of an AE is equal to the date of first dose of study medication and the AE was 
documented as a PTE on the eCRF, the AE will be classified as a PTE. Otherwise, the AE will 
be flagged as a TEAE. 
 
Page 38  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 When calculating the frequency and percentage of subjects who reported TEAEs, a subject will 
be counted only once for each SOC or HLT or PT when multiple TEAEs are coded to the same 
SOC or HLT or PT. Thus, if a subject has two distinct AEs, each of which corresponds to a 
distinct PT but both of which correspond to the same HLT, then that subject will be counted once 
at that HLT  subject-count summary level and once at each of the two preferred-term subject-
count summary levels within an HLT. This same logic is extended to all PT nested within HLT 
that is in-turn nested within an SOC. For the intensity summaries, if a subject reports multiple 
treatment-emergent AEs coded to the same SOC or HLT or PT then the TEAE with maximum 
intensity will be included in the summary.  
TEAEs with missing intensity will be listed as such in the TEAE listings, however, will be 
summarized as severe in summary tables. If the relationship of a TEAE is missing, the 
relationship for the TEAE  will be considered to have been related. In the cases where a subject 
has multiple TEAEs with the same SOC or HLT or PT, the TEAE with the maximum intensity or 
strongest relationship will be summarized.  
Most frequent TEAEs are defined as events that occur in at least 3% of subjects within the 
treatment group.  
TEAEs will include the number and percentage of subjects as follows:  
ï‚· Overview of Treatment-Emergent Adverse Events  
ï‚· Treatment-Emergent Adverse Events by System Organ Class, High Level Term, and 
Preferred Term 
ï‚· Subject Mappings of Treatment-Emergent Adverse Events 
ï‚· Treatment-Emergent Adverse Events by System Organ Class  
ï‚· Treatment-Emergent Adverse Events by High Level Term  
ï‚· Treatment-Emergent Adverse Events by Preferred Term  
ï‚· Treatment-Emergent Adverse Events by Baseline AVA Status, System Organ Class, 
High Level Term, and Preferred Term 
ï‚· Most Frequent Treatment Emergent Adverse Events by Preferred Term  
ï‚· Most Frequent Non-Serious Treatment Emergent Adverse Events by Preferred Term  
ï‚· Relationship of Treatment-Emergent Adverse Events to Study Drug by System Organ 
Class, High Level Term,  and Preferred Term  
ï‚· Intensity of Treatment-Emergent Adverse Events by System Organ Class, High Level 
Term, and Preferred Term  
ï‚· Intensity of Drug-Related Treatment-Emergent Adverse Events by System Organ Class, 
High Level Term, and Preferred Term  
ï‚· Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System 
Organ Class, High Level Term,  and Preferred Term 
 
Page 39  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Subject Mappings for Treatment-Emergent Adverse Events Leading to Study Drug 
Discontinuation 
ï‚· Serious Treatment-Emergent Adverse Events by System Organ Class, High Level Term, 
and Preferred Term 
ï‚· Subject Mappings for Serious Treatment-Emergent Adverse Events 
ï‚· Serious Treatment-Emergent Adverse Events by Baseline AVA Status, System Organ 
Class, High Level Term, and Preferred Term 
ï‚· Adverse Events Related to Study Procedures by System Organ Class, High Level Term, 
and Preferred Term 
ï‚· Treatment-Emergent Infections by System Organ Class, High Level Term, and Preferred 
Term 
ï‚· Pretreatment Events by System Organ Class, High Level Term, and Preferred Term 
ï‚· Pretreatment Serious Events by System Organ Class, High Level Term, and Preferred 
Term 
Data listings will be provided for PTEs, TEAEs, TEAEs leading to study drug discontinuation, 
SAEs, AEs that resulted in death, and AEs occurring more than 30 days post treatment.  
7.13.1.1 Adverse Events of Special Interest 
Based on the mechanism of action of vedolizumab, certain adverse events of special interest 
(AESIs) have been predefined. The categories of adverse events of special interest, and other 
planned analyses, are described below.  
Infusion-Related Reactions (IRRs), including Hypersensitivity Reactions  
The clinical database will be searched for possible IRRs during the reporting period using the 
following MedDRA 19.0 search criteria: 
ï‚· Anaphylactic/anaphylactoid shock conditions Standard MedDRA Query (SMQ) (broad) 
ï‚· Angioedema SMQ (broad)  
ï‚· Hypersensitivity SMQ (broad) 
ï‚· Infusion related reaction HLT 
An AE that is indicated as an infusion site reaction in the eCRF will also be considered an IRR 
AESI. 
Infusion-related AEs will be summarized by SOC, HLT, and PT. In addition, all AEs beginning 
on, or one calendar day after, the dates of study drug infusions will be similarly analyzed.  
Upper Respiratory Tract Infections 
The infections retrieved from the clinical database will be evaluated for upper respiratory tract 
infections during the reporting period using the MedDRA 19 .0 search criteria of:  
 
Page 40  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Upper respiratory tract infections HLT in the Infections and Infestations SOC 
ï‚· Bronchitis PT 
ï‚· Influenza PT 
Upper respiratory tract infections will be summarized by SOC, HLT,  and PT. 
Gastrointestinal (GI) Infections 
The infection reports retrieved from the clinical database were evaluated for GI infections during 
the reporting period using the MedDRA 19.0 search criteria of:  
ï‚· Abdominal and gastrointestinal infections HLT in the Infections and infestations SOC 
ï‚· Gastrointestinal infections HLT of the Gastrointestinal disorders SOC 
GI infections will be summarized by SOC, HLT , and PT. 
Suspected Progressive Multifocal Leukoencephalopathy (PML) 
The protocol incorporates an active screening program in order to identify and manage any case 
of PML (Protocol Section 11.1.1). This program is known as the Risk Assessment and 
Minimization for PML (RAMP). The clinical database will be searched for suspected PML 
reports received within the Infection and Infestation SOC using the MedDRA 19.0 search criteria 
of:  
ï‚· Human polyomavirus infection PT 
ï‚· JC virus infection PT 
ï‚· JC virus test positive PT 
ï‚· Leukoencephalopathy PT 
ï‚· Polyomavirus test positive PT 
ï‚· Progressive multifocal leukoencephalopathy PT 
Suspected PML will be summarized by SOC, HLT and PT along with the results of the RAMP 
screening program. 
Other Infections, including Opportunistic Infections 
The infection reports retrieved from the clinical database, not classified as upper respiratory tract 
infections (URTI s), GI infections, or suspected PML will be searched using the MedDRA 19.0 
search criteria of:  
ï‚· Infections and Infestations SOC  
The following reports will then be excluded: 
ï‚· Abdominal and gastrointestinal infections HLT  
ï‚· URTI HLT 
ï‚· Bronchitis PT 
 
Page 41  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 ï‚· Influenza PT 
ï‚· Human polyomavirus infection PT 
ï‚· JC virus infection PT 
ï‚· JC virus test positive PT 
ï‚· Leukoencephalopathy PT 
ï‚· Polyomavirus test positive PT 
ï‚· Progressive multifocal leukoencephalopathy PT 
Other infections will be summarized by SOC, HLT and PT. 
Liver Injury 
The clinical database will be searched for reports of liver injury using the following MedDRA 
19.0 search criteria: 
ï‚· Cholestasis and jaundice of hepatic origin SMQ (broad)  
ï‚· Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions SMQ 
(broad) 
ï‚· Hepatitis, non-infectious SMQ (broad)  
ï‚· Liver related investigations, signs and symptoms SMQ (narrow)  
ï‚· Liver infections SMQ (b road) 
Liver Injuries will be summarized by SOC, HLT and PT. 
Malignancies 
The clinical database will be searched for reports of malignancy using the MedDRA 19.0 search 
criteria of:  
ï‚· Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC. 
Malignancies will be summarized by SOC, HLT, and PT. 
7.13.2 Clinical Laboratory Evaluations 
Clinical laboratory tests will be evaluated and presented using the International System of Units 
(SI) unless otherwise stated. Refer to Appendix A  for scheduled measurements for clinical 
laboratory tests and to Table 7.i for a list of all Protocol-specified clinical laboratory tests. The 
central laboratory will perform laboratory tests for serum chemistries, hematology, and 
urinalysis. All laboratory test parameters will be displayed in individual subject data listings in 
SI units. For test results not in SI units, the conversion to SI units will be done in the derived 
analysis data sets using the known conversion factors. If necessary, SI units from the central 
laboratory may be converted to Takedaâ€™s preferred SI units in the derived dataset. All summaries 
and analyses will be based on the values using these preferred SI units. If a lab test with 
quantitative results has a value that is reported using a non-numeric qualifier (e.g., less than (<) a 
 
Page 42  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 certain value, or greater than (>) a certain value), the given numeric value will be used in the 
summary statistics, ignoring the non-numeric qualifier. 
The following summaries of hematology, serum chemistry and urinalysis lab tests will be 
presented for each scheduled time point (Baseline, each post-Baseline visit, and Final Visit). 
The observed and change from Baseline values will be based on a single data value selected 
according to the window conventions described in Table 7.a , Table 7.b, Table 7 .c, and Table 7.d. 
Note that â€œcharacterâ€ urinalysis parameters will only be listed. 
Shifts in laboratory test values will be presented as cross-tabulations (Baseline versus each post-
Baseline visit and Final Visit) of numbers of subjects with low, normal,  and high values relative 
to the normal range used at the central laboratory. This classification will be based on the low, 
normal, and high alert flags reported by the central laboratory. If a subject has multiple values 
within a particular visit window, the most extreme result will be used for summary. Shift tables 
will be produced for all clinical laboratory tests with reference ranges.  
Listings of all clinical safety laboratory data will be provided, including hematology, serum 
chemistry, and urinalysis. Laboratory data outside of the normal reference range will be 
indicated in the listings. In addition, markedly abnormal values (MAVs) will be flagged. The 
listing will also include the site, subject number, age (at informed consent), gender, treatment 
group, study visit, and sample collection date. 
 
Page 43  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Table 7.i Protocol-Specified Clinical Laboratory Tests 
Hematology  Serum Chemistry  Urinalysis (dipstick)  
RBC 
WBC w/ differential  
Hemoglobin  
Hematocrit  
Platelets 
PT/INR ALT 
Albumin 
Alkaline phosphatase  
Amylase 
Lipase 
AST  
Total and direct bilirubin  
Total protein  
Creatinine  
Blood urea nitrogen  
Creatine kinase  
GGT 
Potassium  
Sodium 
Calcium 
Chloride 
Bicarbonate  
Magnesium  
Phosphorus  
Uric Acid  
Glucose  
eGFR (for MREn subjects only)  Bilirubin 
Blood  
Glucose 
Ketones 
Leukocyte esterase  
Nitrite 
pH 
Protein  
Specific Gravity  
Other: 
HIV 
Hepatitis panel, including HBsAg and anti -HCV 
CRP 
AVA 
Quantiferon for TB  Beta hCG and Urine Pregnancy hCG  
(female subjects of childbearing potential)  
FSH, if menopause is suspected  
Stool: 
Fecal calprotectin   
FSH=follicle-stimulating hormone, GGT= Î³-Glutamyl transferase, HBsAg=hepatitis B surface antigen, hCG=human chorionic 
gonadotropin, PT=prothrombin time, RBC=red blood cells. 
MAV laboratory results, identified as defined by the criteria in Appendix E , will be tabulated. 
MAV tables will include all laboratory parameters with available MAV criteria. 
Additionally, for each subject with a MAV for a parameter, all the subjectâ€™s values of that 
parameter will be listed.  
Subject mappings for the MAV summary table will be provided. 
7.13.3 Vital Signs 
Vital signs,  including pulse, systolic blood pressure (SBP), diastolic blood pressure (DBP), 
temperature, respiration rate, and weight, will be summarized. Vital sign values will be tabulated 
at Baseline and at each post-Baseline visit, and change from Baseline will be calculated for each 
post-Baseline visit and Final Visit. Refer to Appendix A  for scheduled measurements for v ital 
signs. 
Criteria for MAV vital signs are listed in Appendix F . The number and percentage of subjects 
who meet MAV vital signs criteria will be summarized.  
 
Page 44  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 Vital signs data will be listed by site number and subject number. In addition, markedly 
abnormal values (MAVs) will be flagged. The listing will include site number, subject number, 
treatment group, age, gender, study visit,  and assessment date. 
7.13.4 12-Lead ECGs 
Overall ECG interpretation category (normal, not clinically significant abnormal, clinically 
significant abnormal) is collected by eCRF at Screening.  
ECG data will be listed by site number and subject number. The listing will include site number, 
subject number, treatment group, age, gender, study visit, and assessment date.  
7.13.5 Other Observations Related to Safety 
The other safety endpoints to be included in the listings are the liver function tests for increase, 
sign and symptoms, event history, and test results. Also included are the details of infection, their 
diagnostic tests, cause/origin, history preceding event s, and associated symptoms. The 
malignancy status based on d iagnostic tests, stage, the risk factors, and details will also be listed. 
The PML checklist that includes the PML criteria, their response, symptoms, result,  and 
abnormality will be listed by visit. The listings will also include the PML algorithm and the 
responses by visit. 
7.14 I NTERIM ANALYSIS 
Formal interim analyses will be conducted for final efficacy at Weeks 14, 26, and 5 2, and for 
safety using the FAS and FAS-Extension, unless otherwise noted. 
The Week 14 interim analysis will include the secondary and additional endpoints along with all 
safety endpoints, including: 
ï‚· Disposition of Subjects  
ï‚· Demographic and Baseline Characteristics  
ï‚· Medication History and Concomitant Medications  
ï‚· Study Drug Exposure and Compliance  
ï‚· Secondary Efficacy Endpoints: endoscopic remission at Week 14, endoscopic response at 
Week 14, clinical response at Week 10, clinical remission at Week 10  
ï‚· Additional Efficacy Endpoints: 25% and 75% reduction of SES-CD at Week 14, 
normalization of CRP at Week 10, change from Baseline to Week 14 in fecal 
calprotectin, change from Baseline to Week 14 in IBDQ total and subscale scores, change 
from Baseline to Week 14 in EQ-5D utility score and VAS score, change from Baseline 
to Week 14 in percent work time missed due to CD, change from Baseline to Week 14 in 
percent impairment while working due to CD, change from Baseline to Week 14 in 
percent overall work impairment due to CD, change from Baseline to Week 14 in percent 
activity impairment due to CD  
ï‚· Safety Endpoints: AEs,  AESIs, laboratory results, vital signs, ECGs  
 
Page 45  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 For subjects who have completed the Week 26 visit by the Week 14 interim lock date, the 
endpoints listed below for Week 26 will be included in the Week 14 interim analysis for 
publication purposes. 
The Week 26 interim analysis will include the endpoints listed above for Week 14 as well as 
added primary, secondary, and additional endpoints, including: 
ï‚· Primary Efficacy Endpoint: endoscopic remission at Week 26  
ï‚· Secondary Efficacy Endpoints: complete mucosal healing at Week 26, endoscopic 
response at Week 26, clinical response at Week 26, clinical remission at Week 26  
ï‚· Additional Efficacy Endpoints: 25% and 75% reduction of SES-CD at Week 26, no 
granulocytes present in bowel biopsy at Week 26, change in histology at Week 26, 
normalization of CRP at Week 26, change from Baseline to Week 26 in fecal 
calprotectin, change from Baseline to Week 26 in IBDQ total and subscale scores, change 
from Baseline to Week 26 in EQ-5D utility score and VAS score, change from Baseline 
to Week 26 in percent work time missed due to CD, change from Baseline to Week 26 in 
percent impairment while working due to CD, change from Baseline to Week 26 in 
percent overall work impairment due to CD, change from Baseline to Week 26 in percent 
activity impairment due to CD  
The Week 52 interim analysis will include the endpoints listed above for Weeks 14 and 26 as 
well as added secondary and additional endpoints, including: 
ï‚· Secondary Efficacy Endpoints: complete mucosal healing at Week 52, endoscopic 
response at Week 52, clinical response at Week 52, clinical remission at Week 52, 
durable clinical remission 
ï‚· Additional Efficacy Endpoints: change from Baseline to Week 26 in individual MREn 
parameters for each ileocolonic segment and for more proximal bowel segments (using 
the FAS-MREn), change from Baseline to Week 52 in individual MREn parameters for 
each ileocolonic segment and for more proximal bowel segments (using the FAS-MREn), 
MaRIA score < 7 at Week 26 and Week 52 globally and on a per segment basis, 25% and 
75% reduction of SES-CD at Week 52, no neutrophils present in bowel biopsy at Week 
52, change in histology at Week 52, normalization of CRP at Weeks 38 and 52, change 
from Baseline to Weeks 38 and 52 in fecal calprotectin, AVA positive at Week 52, 
positive neutralizing AVA at Week 52, clinical response at Weeks 38 and 46, clinical 
remission at Week 38 and 46, change from Baseline to Weeks 38 and 52 in IBDQ total 
and subscale scores, change from Baseline to Weeks 38 and 52 in EQ-5D utility score 
and VAS score, change from Baseline to Week 52 in percent work time missed due to 
CD, change from Baseline to Week 52  in percent impairment while working due to CD, 
change from Baseline to Week 52 in percent overall work impairment due to CD, change 
from Baseline to Week 52 in percent activity impairment due to CD 
For the interim analyses outlined above, subgroup analysis of the primary, secondary, and 
additional efficacy endpoints will be conducted on prior TNF-alpha status (naÃ¯ve, failure). 
 
Page 46  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 7.15 C HANGES IN THE STATISTICAL ANALYSIS PLAN  
Not applicable. 
 
Page 47  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality agreement.  
 8.0 REFERENCES 
1. An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to 
Severely Active Crohnâ€™s Disease Treated With Vedolizumab IV, Takeda Development 
Center Americas, Inc., Protocol No. MLN0002-3028, Amendment 04, dated 28 April, 2016. 
2. Daperno M, Dâ€™Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development 
and validation of a new, simplified endoscopic activity score for Crohnâ€™s disease: the SES-
CD. Gastrointest Endosc 2004; 60(4):505-12. 
3. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohnâ€™s disease activity 
index. National Cooperative Crohnâ€™s Disease Study. Gastroenterology 1976; 70(3):439-44. 
4. Geboes K and Dalle I. Influence of treatment on morphological features of mucosal 
inflammation. Gut 2002; 50 Suppl 3:iii37-iii42. 
 
 
 
Page 48 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 9.0 APPENDICES  
Appendix A Schedule of Study Procedures 
 
  

 
Page 49 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
  
  

 
Page 50 of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 (a) Week 26 is the final visit for subjects completing at Week 26 (Study Part A) and for subjects who continue to extension of treatment (Study Part B) this is a standard visit. 
(b) Assessment completed or sample taken pre-dose. 
(c) Collect prior biologic medications that stopped prior to screening. 
(d) Height collected only at the Screening Visit. 
(e) The components of the CDAI score to determine eligibility must be completed within 14 days prior to enrollment using hematocrit results collected during Screening. 
(f) CDAI score components are to be performed prior to dosing; the total CDAI score will be calculated once results are available for all components. 
(g) Biopsies to be collected at Screening, Week 26, and Week 52 for those completing the study. 
(h) MREn conducted only at pre-identified sites. During the Screening period MREn should be performed prior to ileocolonoscopy. At Week 26 and Week 52 MREn to be performed prior 
to ileocolonoscopy either on the same day or at least 7 days before the ileocolonoscopy within the permitted time window for Week 26 or Week 52 procedures. Sites participating in 
MREn will need to check eGFR prior to procedure at Screening, Week 26, and Week 52 (using eGFR calculated from the Week 22 Visit for the Week 26 MREn and from the Week 46 
Visit for the Week 52 MREn). 
(i) Stool sample to be collected and sent to central laboratory for evaluation of fecal calprotectin. 
(j) QuantiFERONÂ® test or tuberculin skin test only. 
(k) Hepatitis and HIV testing only done at the Screening Visit. 
(l) Only subjects participating in MREn to have a sample for serum creatinine collected at Week 22 and Week 46. Samples will be sent to central laboratory for evaluation of eGFR. 
(m) DNA and RNA samples will be collected on Day 1 only for subjects that have consented to the Pharmacogenomic study. 
(n) Serum pregnancy completed at Screening and at the Postdose 18 Week Safety Follow-up Visit; urine pregnancy to be completed at other visits. 
(o) Long Term Follow-up Wallet card will be given to subjects at the last clinical visit.
 
Page 51  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix B Simple Endoscopic Score for Crohn's Disease (SES- CD) 
 Simple Endoscopic Score for Crohnâ€™s Disease values  
Variable 0 1 2 3 
Size of ulcers  None Aphthous ulcers  
 (Ã˜ 0.1 to 0.5 cm ) Large ulcers  
 (Ã˜ 0.5 to 2 cm)  Very large ulcers  
 (Ã˜ >2 cm)  
Ulcerated surface  None <10% 10-30% >30% 
Affected surface  Unaffected segment  <50% 50-75% >75% 
Presence of narrowings  None Single, can be passed  Multiple, can be passed  Cannot be passed  
Ã˜, Diameter.  
Source: Adapted from Daperno M, Dâ€™Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, 
simplified endoscopic activity score for Crohnâ€™s disease: the SES-CD. Gastrointest Endosc 2004; 60(4):505-12 [ 2]. 
  
 
Page 52  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix C Crohn's Disease Activity Index (CDAI) 
 
Source: Adapted from: Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohnâ€™s disease activity index. 
National Cooperative Crohnâ€™s Disease Study. Gastroenterology 1976; 70 (3):439-44 [ 3]. 
(a) If hematocrit subtotal < 0, enter 0. 
(b) If body weight subtotal < -10, enter -10.   

 
Page 53  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix D Geographic Regions 
Region Countries  
North America  Canada Puerto Rico  United States  
Western / Northern 
Europe Austria 
France 
Ireland 
Norway 
Sweden Belgium 
Germany 
Italy 
Portugal 
Switzerland  Denmark 
Iceland 
Netherlands  
Spain 
United Kingdom  
Central Europe  Czech Republic  
Poland 
Slovak Republic  Greece 
Romania Hungary 
Serbia 
Eastern Europe  Bulgaria 
Latvia 
Turkey Estonia 
Malta 
Ukraine Israel 
Russia 
Africa / Asia / Australia  Australia 
New Zealand  
Taiwan 
South Africa  Hong Kong  
South Korea  
China India 
Malaysia 
Singapore  
  
 
Page 54  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix E Criteria for Identification of Markedly Abnormal Laboratory Values  
Hematologyâ€”Criteria for Markedly Abnormal Values 
      
   Conventional Units   Takeda Preferred SI Units  
    Markedly      Markedly  
    Abnormal    Abnormal  
Parameter  Gender Age Units Value  Units Value 
Red Blood 
Cells Both Adult Ã—106 
cells/ÂµL < 0.8 Ã— LLN, > 1.2 Ã— 
ULN  Ã—1012 
cells/L < 0.8 Ã— LLN, > 1.2  Ã— 
ULN 
White Blood 
Cells Both  Adult Ã—103 
cells/ÂµL <0.5 Ã— LLN, > 1.5 Ã— 
ULN  Ã—109 cells/L < 0.5 Ã— LLN, > 1.5 Ã— 
ULN 
Hemoglobin  Both Adult g/dL < 0.8 Ã— LLN, > 1.2 
Ã— ULN  g/L < 0.8 Ã— LLN, > 1.2 Ã— 
ULN 
Hematocrit  Both Adult % < 0.8 Ã— LLN, > 1.2 
Ã— ULN  Fraction of 
1 < 0.8 Ã— LLN, > 1.2 Ã— 
ULN 
Platelets Both Adult Ã—103/ÂµL < 75, > 600   Ã—109 /L < 75, > 600  
MCV Both Adult fL < 70, > 110   fL < 70, > 110  
Segmented 
Neutrophils 
(Absolute)  Both Adult Ã—103 
cells/ÂµL < 0.5 Ã— LLN, > 1.5 
Ã— ULN  Ã— 109 
cells/L < 0.5 Ã— LLN, > 1.5 Ã— 
ULN 
Segmented 
Neutrophils 
(Relative)  Both Adult % < 0.5 Ã— LLN, > 1.5 
Ã— ULN  Fraction of 
1 < 0.5 Ã— LLN, > 1.5 Ã— 
ULN 
Lymphocytes 
(Absolute)  Both Adult Ã—103 
cells/ÂµL < 0.5 Ã— LLN, > 1.5 
Ã— ULN  Ã— 109 
cells/L < 0.5Ã— LLN, > 1.5 Ã— 
ULN 
Lymphocytes 
(Relative)  Both Adult % < 0.5 Ã— LLN, > 1.5 
Ã— ULN  Fraction of 
1 < 0.5 Ã— LLN, > 1.5 Ã— 
ULN 
Monocytes 
(Absolute)  Both Adult Ã—103 
cells/ÂµL > 2 Ã— ULN   Ã— 109 
cells/L > 2 Ã— ULN  
Monocytes 
(Relative)  Both Adult % > 2 Ã— ULN   Fraction of 
1 > 2 Ã— ULN  
Eosinophils 
(Absolute)  Both Adult Ã—103 
cells/ÂµL > 2 Ã— ULN   Ã— 109 
cells/L > 2 Ã— ULN  
Eosinophils 
(Relative)  Both Adult % > 2 Ã— ULN   Fraction of 
1 > 2 Ã— ULN  
Basophils 
(Absolute)  Both Adult Ã—103 
cells/ÂµL > 3 Ã— ULN   Ã— 109 
cells/L > 3 Ã— ULN  
Basophils 
(Relative)  Both Adult % > 3 Ã— ULN   Fraction of 
1 > 3 Ã— ULN  
Reticulocytes 
(Relative)  Both Adult % of 
erythrocyte
s > 3.0  Fraction of 
1 > 0.030 
PT Both Adult Sec > 1.5 Ã— ULN   Sec > 1.5 Ã— ULN  
APTT Both Adult Sec > 1.5 Ã— ULN   Sec > 1.5 Ã— ULN  
INRâ€  Both Adult NA > 1.5  NA > 1.5 
LLN = lower limit of normal or lower reference limit; ULN = upper limit of normal or upper reference limit  
â€  Values are for subjects without anticoagulation, based on the normal range provided above for PT. 
  
 
Page 55  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Chemistryâ€”Criteria for Markedly Abnormal Values 
      
   Conventional Units   Takeda Preferred SI Units  
    Markedly    Markedly  
    Abnormal    Abnormal  
Parameter  Gender Age 
(years) Units Values  Units Value 
Alanine 
Aminotransferase  Both Adult U/L >3 Ã— ULN   U/L >3 Ã— ULN  
Albumin  Both Adult g/dL < 2.5  g/L  < 25 
Alkaline 
Phosphatase  Both >20 U/L >3 Ã— ULN   U/L >3 Ã— ULN  
Aspartate 
Aminotransferase  Both Adult U/L >3 Ã— ULN   U/L > 3 Ã— ULN  
Total Bilirubin  Both Adult mg/dL > 2.0  Âµmol/L > 34.2 
Total Protein  Both Adult g/dL < 0.8 Ã— LLN, > 1.2 
Ã— ULN  g/L < 0.8 Ã— LLN, > 
1.2 Ã— ULN  
Creatinine  Both Adult mg/dL > 2  Âµmol/L > 177  
Blood Urea 
Nitrogen  Both Adult mg/dL > 30  mmol/L > 10.7    
Creatine Kinase  Both Adult U/L >5 Ã— ULN   U/L >5 Ã— ULN  
ï§-Glutamyl 
Transferase  Both Adult U/L >3 Ã— ULN   U/L >3 Ã— ULN  
Potassium (serum)  Both Adult mEq/L < 3.0, > 6.0   mmol/L < 3.0, > 6.0  
Sodium Both Adult mEq/L < 130, > 150   mmol/L < 130, > 150  
Direct Bilirubin  Both Adult mg/dL >2 Ã— ULN   Âµmol/L >2 Ã— ULN  
Calcium Both Adult mg/dL < 7.0, > 11.5   mmol/L < 1.75, > 2.88  
Uric Acid  Both Adult mg/dL > 13.0  Âµmol/L > 773 
Glucose Both Adult  mg/dL 
 < 50, > 350   mmol/L < 2.8, > 19.4  
Magnesium  Both Adult mg/dL < 1.2, > 3.0   mmol/L < 0.5, > 1.2  
Phosphorus  Both Adult mg/dL < 1.6, > 6.2   mmol/L < 0.52, > 2.000  
Total Cholesterol  Both Adult mg/dL > 300  mmol/L > 7.72 
Triglycerides  Both Adult mg/dL > 2.5 Ã— ULN   mmol/L > 2.5 Ã— ULN  
Chloride  Both Adult mEq/L < 75, > 126   mmol/L < 75, > 126  
HbA1c Both Adult % > 7  Fraction 
of 1 > 0.07 
Bicarbonate  Both Adult mEq/L < 8.0  mmol/L < 8.0 
Prolactin  Both Adult Âµg/L >10 Ã— ULN   pmol/L >10 Ã— ULN  
Progesterone  Female Adult ng/mL Progesterone/  
Estrogen - 26:1â€   nmol/L Progesterone/  
Estrogen - 26:1â€  
LLN = lower limit of normal or lower reference limit; ULN = upper limit of normal or upper reference limit   
â€ Any abnormal values should be interpreted with the ratio progesterone/estrogen and SHBP values: Higher levels of SHBP lower 
levels of free progesterone. 
  
 
Page 56  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Serum Chemistryâ€”Criteria for Markedly Abnormal Values (Continued) 
      
   Conventional Units   Takeda Preferred SI Units  
    Markedly    Markedly  
    Abnormal    Abnormal  
Parameter  Gender Age 
(years) Units Values  Units Value 
Thyroid 
Stimulating 
Hormone  Both Adult mU/L < 0.8 Ã— LLN,  
> 2.0 Ã— ULN   mU/L < 0.8 Ã— LLN,  
> 2.0 Ã— ULN  
Vitamin B12  Both Adult pg/mL < 125  pmol/L < 92 
Folate Both Adult ng/mL < 2.2, > 17.5   nmol/L < 5.0, > 39.7  
Amylase Both Adult U/L >2 Ã— ULN   U/L >2 Ã— ULN  
Lipase Both Adult U/L >3 Ã— ULN   U/L >3 Ã— ULN  
LLN = lower limit of normal or lower reference limit; ULN = upper limit of normal or upper reference limit   
â€ Any abnormal values should be interpreted with the ratio progesterone/estrogen and SHBP values: Higher levels of SHBP lower 
levels of free progesterone. 
 
 
Page 57  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix F Criteria for Abnormal Changes from Baseline of Vital Signs  
Parameter  Unit Lower Criteria  Upper Criteria  
Systolic Arterial Pressure  (mmHg) < 85 > 180 
Diastolic Arterial Pressure  (mmHg) < 50 > 110 
Pulse (bpm) < 50 > 120 
Body Temperature  oC < 35.6 > 37.7 
 oF < 96.1 > 99.9  
 
Both the criterion value and the change from Baseline must be met. 
 
 
Page 58  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Appendix G: Patient Related Outcomes  
 
Quality of Life questionnaire: IBDQ 
 Sub-score Calculation  
 IBDQ Bowel symptoms score  Sum of (Q1, Q5, Q9, Q13, Q17, Q20, Q22, 
Q24, Q26, Q29), Ranging from 10 to 70, 10 
questions  
 IBDQ Emotional function score  Sum of (Q3, Q7, Q11, Q15, Q19, Q21, Q23, 
Q25, Q27, Q30, Q31, Q32), Ranging from 12 
to 84, 12 questions  
 IBDQ Social function score  Sum of (Q4, Q8, Q12, Q16,Q28), Ranging 
from 5 to 35, 5 questions  
 IBDQ Systemic symptoms score  Sum of (Q2, Q6, Q10, Q14,Q18), Ranging 
from 5 to 35, 5 questions  
Note For each component score above, if 50% or less of the component score is missing at a visit, the  
MEAN of the remaining component score will be imputed as the value for the missing 
component score. If more than 50% of the component score is missing for the item, the imputed 
value will be set to missing.  
 IBDQ score  Sum of (bowel, emotion, social, sys tem) 
Note If any of the component score is missing at a visit, the imputed value will be set to missing.  
 
  
 
Page 59  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Quality of Life questionnaire: EQ-5D 
 Sub-score Calculation  
 EQ-5D mobility component score  Ranging from 1 to 3  
 EQ-5D self-care component score  Ranging from 1 to 3  
 EQ-5D usual activities  component 
score Ranging from 1 to 3  
 EQ-5D pain/discomfort component 
score Ranging from 1 to 3  
 EQ-5D anxiety/depression  
component score  Ranging from 1 to 3  
EQ-5D Index Score  1. If any of the 5  components above are missing, the index score is 
missing. Skip the remaining steps below.  
2. Count the number of component scores with a response > 1. If the count 
is non-zero, subtract 1. If the count is zero, leave it as 0.  
3. Count the number of component scores w ith a response equal to 2. If the 
count is non -zero, subtract 1. If the count is zero, leave it as 0.  
4. Count the number of component scores with a response equal to 3. If the 
count is non -zero, subtract 1. If the count is zero, leave it as 0.  
5. Calculat e the index score using the following formula:  
EQâˆ’5D index  score =1 âˆ’ 0.146016 Ã—(1,if mobility =
2;0,if mobility â‰ 2)âˆ’0.557685 Ã—(1,if mobility =
3;0,if mobility â‰ 3)âˆ’0.1753425 Ã—(1,if self âˆ’care =2;0,if self âˆ’
care â‰ 2)âˆ’ 0.4711896 Ã—(1,if self âˆ’care =3;0,if self âˆ’care â‰ 
3)âˆ’0.1397295 Ã—(1,if usual  activities =2;0,if usual  activities â‰ 
2)âˆ’0.3742594 Ã—(1,if usual  activities =3;0,if usual  activities â‰ 
3)âˆ’0.1728907 Ã—(1,if pain /discomfort =2;0,if pain /
discomfort â‰ 2)âˆ’ 0.5371011 Ã—(1,if pain /discomfort =
3;0,if pain /discomfort â‰ 3)âˆ’0.156223 Ã—(1,if anxiety/
depression =2;0,if anxiety /depression â‰ 2)âˆ’0.4501876 Ã—
(1,if anxiety /depression =3;0,if anxiety /depression â‰ 3)+
0.1395949 Ã—(result  from  Step  #2)âˆ’0.0106868 Ã—
(result  from  Step  #3)2+0.1215579 Ã—(result  from  Step  #4)+
0.0147963 Ã—(result  from  Step  #4)2  
EQ5D VAS  On a scale of 0 to 100, where 0 is the worst imaginable health state and 
100 is the best imaginable health state.  
 
  
 
Page 60  of 60  
 
Printed or downloaded documents must be verified against the effective version.  
CONFIDENTIAL INFORMATION  
Do not distribute outside of Takeda without a confidentiality ag reement.  
 Quality of Life questionnaire : WPAI-CD 
 Dimension  Calculation  
 Absenteeism  
Percent work time missed due to health  Q2
Q2+Q4  
 Presenteeism  
Percent impairment while working due to health  Q5
10  
 Overall Work Impairment  
Percent overall work impairment due to health  Q2
Q2+Q4+[(1âˆ’Q2
Q2+Q4)Ã—Q5
10]  
 Daily Activities Impairment  
Percent activity impairment due to health  Q6
10  
Note WPAI-CD dimension  scores are multiplied by 100 to be expressed in percentages.  
 